<?xml version="1.0" encoding="UTF-8"?>
<OAI-PMH xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.openarchives.org/OAI/2.0/ http://www.openarchives.org/OAI/2.0/OAI-PMH.xsd">
  <responseDate>2024-05-03T02:28:24Z</responseDate>
  <request verb="GetRecord" identifier="oai:pubmedcentral.nih.gov:10186444" metadataPrefix="pmc">https:/www.ncbi.nlm.nih.gov/pmc/oai/oai.cgi</request>
  <GetRecord>
    <record>
      <header>
        <identifier>oai:pubmedcentral.nih.gov:10186444</identifier>
        <datestamp>2023-05-17</datestamp>
        <setSpec>bmjo</setSpec>
        <setSpec>pmc-open</setSpec>
      </header>
      <metadata>
        <article xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xsi:schemaLocation="https://jats.nlm.nih.gov/ns/archiving/1.3/ https://jats.nlm.nih.gov/archiving/1.3/xsd/JATS-archivearticle1-3.xsd" dtd-version="1.3" xml:lang="en" article-type="research-article">
          <processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats">
            <restricted-by>pmc</restricted-by>
          </processing-meta>
          <front>
            <journal-meta>
              <journal-id journal-id-type="nlm-ta">BMJ Open</journal-id>
              <journal-id journal-id-type="iso-abbrev">BMJ Open</journal-id>
              <journal-id journal-id-type="hwp">bmjopen</journal-id>
              <journal-id journal-id-type="publisher-id">bmjopen</journal-id>
              <journal-title-group>
                <journal-title>BMJ Open</journal-title>
              </journal-title-group>
              <issn pub-type="epub">2044-6055</issn>
              <publisher>
                <publisher-name>BMJ Publishing Group</publisher-name>
                <publisher-loc>BMA House, Tavistock Square, London, WC1H 9JR</publisher-loc>
              </publisher>
            </journal-meta>
            <article-meta>
              <article-id pub-id-type="accession">PMC10186444</article-id>
              <article-id pub-id-type="pmcid">PMC10186444</article-id>
              <article-id pub-id-type="pmc-uid">10186444</article-id>
              <article-id pub-id-type="pmid">37188469</article-id>
              <article-id pub-id-type="pmid">37188469</article-id>
              <article-id pub-id-type="publisher-id">bmjopen-2022-067657</article-id>
              <article-id pub-id-type="doi">10.1136/bmjopen-2022-067657</article-id>
              <article-categories>
                <subj-group subj-group-type="heading">
                  <subject>Genetics and Genomics</subject>
                </subj-group>
                <subj-group subj-group-type="hwp-journal-coll">
                  <subject>1506</subject>
                  <subject>1697</subject>
                </subj-group>
                <series-title>Protocol</series-title>
              </article-categories>
              <title-group>
                <article-title>Implementation of a culturally competent <italic toggle="yes">APOL1</italic> genetic testing programme into living donor evaluation: A two-site, non-randomised, pre–post trial design</article-title>
              </title-group>
              <contrib-group>
                <contrib id="author-86398513" contrib-type="author">
                  <contrib-id contrib-id-type="orcid" authenticated="false">http://orcid.org/0000-0003-3264-8082</contrib-id>
                  <name>
                    <surname>Smith</surname>
                    <given-names>Justin D</given-names>
                  </name>
                  <xref rid="aff1" ref-type="aff">1</xref>
                  <xref rid="aff2" ref-type="aff">2</xref>
                </contrib>
                <contrib id="author-100420200" contrib-type="author">
                  <contrib-id contrib-id-type="orcid" authenticated="false">http://orcid.org/0000-0003-2662-7023</contrib-id>
                  <name>
                    <surname>Agrawal</surname>
                    <given-names>Akansha</given-names>
                  </name>
                  <xref rid="aff3" ref-type="aff">3</xref>
                </contrib>
                <contrib id="author-100420236" contrib-type="author">
                  <contrib-id contrib-id-type="orcid" authenticated="false">http://orcid.org/0000-0001-5725-2872</contrib-id>
                  <name>
                    <surname>Wicklund</surname>
                    <given-names>Catherine</given-names>
                  </name>
                  <xref rid="aff4" ref-type="aff">4</xref>
                </contrib>
                <contrib id="author-100420355" contrib-type="author">
                  <contrib-id contrib-id-type="orcid" authenticated="false">http://orcid.org/0000-0003-4664-0495</contrib-id>
                  <name>
                    <surname>Duquette</surname>
                    <given-names>Debra</given-names>
                  </name>
                  <xref rid="aff3" ref-type="aff">3</xref>
                </contrib>
                <contrib id="author-100420374" contrib-type="author">
                  <contrib-id contrib-id-type="orcid" authenticated="false">http://orcid.org/0000-0002-9344-9928</contrib-id>
                  <name>
                    <surname>Friedewald</surname>
                    <given-names>John</given-names>
                  </name>
                  <xref rid="aff3" ref-type="aff">3</xref>
                </contrib>
                <contrib id="author-100420426" contrib-type="author">
                  <name>
                    <surname>Rasmussen</surname>
                    <given-names>Luke V</given-names>
                  </name>
                  <xref rid="aff5" ref-type="aff">5</xref>
                </contrib>
                <contrib id="author-100420460" contrib-type="author">
                  <contrib-id contrib-id-type="orcid" authenticated="false">http://orcid.org/0000-0002-7000-9014</contrib-id>
                  <name>
                    <surname>Gacki-Smith</surname>
                    <given-names>Jessica</given-names>
                  </name>
                  <xref rid="aff6" ref-type="aff">6</xref>
                </contrib>
                <contrib id="author-61696418" contrib-type="author">
                  <name>
                    <surname>Tandon</surname>
                    <given-names>S. Darius</given-names>
                  </name>
                  <xref rid="aff7" ref-type="aff">7</xref>
                </contrib>
                <contrib id="author-88299044" contrib-type="author">
                  <contrib-id contrib-id-type="orcid" authenticated="false">http://orcid.org/0000-0001-8655-1484</contrib-id>
                  <name>
                    <surname>Muhammad</surname>
                    <given-names>Lutfiyya N</given-names>
                  </name>
                  <xref rid="aff8" ref-type="aff">8</xref>
                </contrib>
                <contrib id="author-77706910" contrib-type="author">
                  <name>
                    <surname>Yancy</surname>
                    <given-names>Clyde W</given-names>
                  </name>
                  <xref rid="aff9" ref-type="aff">9</xref>
                </contrib>
                <contrib id="author-100420486" contrib-type="author">
                  <name>
                    <surname>Dong</surname>
                    <given-names>Siyuan</given-names>
                  </name>
                  <xref rid="aff10" ref-type="aff">10</xref>
                </contrib>
                <contrib id="author-100420552" contrib-type="author">
                  <contrib-id contrib-id-type="orcid" authenticated="false">http://orcid.org/0000-0002-3438-9638</contrib-id>
                  <name>
                    <surname>Cooper</surname>
                    <given-names>Matthew</given-names>
                  </name>
                  <xref rid="aff11" ref-type="aff">11</xref>
                </contrib>
                <contrib id="author-100420562" contrib-type="author">
                  <name>
                    <surname>Gilbert</surname>
                    <given-names>Alexander</given-names>
                  </name>
                  <xref rid="aff12" ref-type="aff">12</xref>
                </contrib>
                <contrib id="author-100420718" contrib-type="author">
                  <name>
                    <surname>Shetty</surname>
                    <given-names>Aneesha</given-names>
                  </name>
                  <xref rid="aff13" ref-type="aff">13</xref>
                </contrib>
                <contrib id="author-43631839" contrib-type="author" corresp="yes">
                  <contrib-id contrib-id-type="orcid" authenticated="false">http://orcid.org/0000-0003-0969-1998</contrib-id>
                  <name>
                    <surname>Gordon</surname>
                    <given-names>Elisa J</given-names>
                  </name>
                  <xref rid="aff14" ref-type="aff">14</xref>
                </contrib>
              </contrib-group>
              <aff id="aff1"><label>1</label><institution content-type="department">Department of Population Health Sciences</institution>, <institution specific-use="Ringgold_12348">Spencer Fox Eccles School of Medicine at the University of Utah</institution>, <addr-line content-type="city">Salt Lake City</addr-line>, <addr-line content-type="state">Utah</addr-line>, <country>USA</country></aff>
              <aff id="aff2"><label>2</label><institution content-type="department">Departments of Psychiatry and Behavioral Sciences and Medical Social Sciences</institution>, <institution>Northwestern University Feinberg School of Medicine</institution>, <addr-line content-type="city">Chicago</addr-line>, <addr-line content-type="state">IL</addr-line>, <country>USA</country></aff>
              <aff id="aff3"><label>3</label><institution content-type="department">Medicine</institution>, <institution specific-use="Ringgold_12244">Northwestern University Feinberg School of Medicine</institution>, <addr-line content-type="city">Chicago</addr-line>, <addr-line content-type="state">Illinois</addr-line>, <country>USA</country></aff>
              <aff id="aff4"><label>4</label><institution content-type="department">Obstetrics and Gynecology</institution>, <institution specific-use="Ringgold_12244">Northwestern University Feinberg School of Medicine</institution>, <addr-line content-type="city">Chicago</addr-line>, <addr-line content-type="state">Illinois</addr-line>, <country>USA</country></aff>
              <aff id="aff5"><label>5</label><institution content-type="department">Division of Health and Biomedical Informatics</institution>, <institution specific-use="Ringgold_12244">Northwestern University Feinberg School of Medicine</institution>, <addr-line content-type="city">Chicago</addr-line>, <addr-line content-type="state">Illinois</addr-line>, <country>USA</country></aff>
              <aff id="aff6"><label>6</label><institution content-type="department">Center for Health Services and Outcomes Research</institution>, <institution specific-use="Ringgold_12244">Northwestern University Feinberg School of Medicine</institution>, <addr-line content-type="city">Chicago</addr-line>, <addr-line content-type="state">Illinois</addr-line>, <country>USA</country></aff>
              <aff id="aff7"><label>7</label><institution content-type="department">Medical Social Sciences</institution>, <institution specific-use="Ringgold_12244">Northwestern University Feinberg School of Medicine</institution>, <addr-line content-type="city">Chicago</addr-line>, <addr-line content-type="state">Illinois</addr-line>, <country>USA</country></aff>
              <aff id="aff8"><label>8</label><institution content-type="department">Department of Preventive Medicine-Division of Biostatistics</institution>, <institution specific-use="Ringgold_3270">Northwestern University</institution>, <addr-line content-type="city">Chicago</addr-line>, <addr-line content-type="state">Illinois</addr-line>, <country>USA</country></aff>
              <aff id="aff9"><label>9</label><institution content-type="department">Department of Medicine-Division of Cardiology</institution>, <institution specific-use="Ringgold_3270">Northwestern University</institution>, <addr-line content-type="city">Evanston</addr-line>, <addr-line content-type="state">Illinois</addr-line>, <country>USA</country></aff>
              <aff id="aff10"><label>10</label><institution content-type="department">Department of Preventive Medicine-Division of Biostatistics</institution>, <institution specific-use="Ringgold_12244">Northwestern University Feinberg School of Medicine</institution>, <addr-line content-type="city">Chicago</addr-line>, <addr-line content-type="state">Illinois</addr-line>, <country>USA</country></aff>
              <aff id="aff11"><label>11</label><institution content-type="department">Surgery</institution>, <institution specific-use="Ringgold_12231">Medical College of Wisconsin</institution>, <addr-line content-type="city">Milwaukee</addr-line>, <addr-line content-type="state">WI</addr-line>, <country>USA</country></aff>
              <aff id="aff12"><label>12</label><institution content-type="department">Medicine</institution>, <institution specific-use="Ringgold_12231">Georgetown University Medical Center</institution>, <addr-line content-type="city">Washington</addr-line>, <addr-line content-type="state">District of Columbia</addr-line>, <country>USA</country></aff>
              <aff id="aff13"><label>13</label><institution content-type="department">Medicine</institution>, <institution specific-use="Ringgold_12216">The University of Arizona College of Medicine Tucson</institution>, <addr-line content-type="city">Tucson</addr-line>, <addr-line content-type="state">Arizona</addr-line>, <country>USA</country></aff>
              <aff id="aff14"><label>14</label><institution content-type="department">Surgery</institution>, <institution specific-use="Ringgold_12328">Vanderbilt University Medical Center</institution>, <addr-line content-type="city">Nashville</addr-line>, <addr-line content-type="state">Tennessee</addr-line>, <country>USA</country></aff>
              <author-notes>
                <corresp><label>Correspondence to</label> Dr Elisa J Gordon; <email>elisa.gordon@vumc.org</email>
</corresp>
              </author-notes>
              <pub-date pub-type="collection">
                <year>2023</year>
              </pub-date>
              <pub-date pub-type="epub">
                <day>15</day>
                <month>5</month>
                <year>2023</year>
              </pub-date>
              <volume>13</volume>
              <issue>5</issue>
              <elocation-id>e067657</elocation-id>
              <history>
                <date date-type="received">
                  <day>24</day>
                  <month>8</month>
                  <year>2022</year>
                </date>
                <date date-type="accepted">
                  <day>14</day>
                  <month>4</month>
                  <year>2023</year>
                </date>
              </history>
              <permissions>
                <copyright-statement>© Author(s) (or their employer(s)) 2023. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ.</copyright-statement>
                <copyright-year>2023</copyright-year>
                <ali:free_to_read/>
                <license>
                  <ali:license_ref specific-use="textmining" content-type="ccbynclicense" start_date="2023-05-15">https://creativecommons.org/licenses/by-nc/4.0/</ali:license_ref>
                  <license-p>This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See: <ext-link ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by-nc/4.0/">http://creativecommons.org/licenses/by-nc/4.0/</ext-link>.</license-p>
                </license>
              </permissions>
              <self-uri xlink:title="pdf" xlink:href="bmjopen-2022-067657.pdf"/>
              <self-uri content-type="reviewers-comments-pdf" xlink:href="bmjopen-2022-067657.reviewer_comments.pdf"/>
              <self-uri content-type="draft-revisions-pdf" xlink:href="bmjopen-2022-067657.draft_revisions.pdf"/>
              <abstract>
                <sec>
                  <title>Introduction</title>
                  <p>While living donor (LD) kidney transplantation is the optimal treatment for patients with kidney failure, LDs assume a higher risk of future kidney failure themselves. LDs of African ancestry have an even greater risk of kidney failure post-donation than White LDs. Because evidence suggests that Apolipoprotein L1 (<italic toggle="yes">APOL1</italic>) risk variants contribute to this greater risk, transplant nephrologists are increasingly using <italic toggle="yes">APOL1</italic> genetic testing to evaluate LD candidates of African ancestry. However, nephrologists do not consistently perform genetic counselling with LD candidates about <italic toggle="yes">APOL1</italic> due to a lack of knowledge and skill in counselling. Without proper counselling, <italic toggle="yes">APOL1</italic> testing will magnify LD candidates’ decisional conflict about donating, jeopardising their informed consent. Given cultural concerns about genetic testing among people of African ancestry, protecting LD candidates’ safety is essential to improve informed decisions about donating. Clinical ‘chatbots’, mobile apps that provide genetic information to patients, can improve informed treatment decisions. No chatbot on <italic toggle="yes">APOL1</italic> is available and no nephrologist training programmes are available to provide culturally competent counselling to LDs about <italic toggle="yes">APOL1</italic>. Given the shortage of genetic counsellors, increasing nephrologists’ genetic literacy is critical to integrating genetic testing into practice.</p>
                </sec>
                <sec>
                  <title>Methods and analysis</title>
                  <p>Using a non-randomised, pre–post trial design in two transplant centres (Chicago, IL, and Washington, DC), we will evaluate the effectiveness of culturally competent <italic toggle="yes">APOL1</italic> testing, chatbot and counselling on LD candidates’ decisional conflict about donating, preparedness for decision-making, willingness to donate and satisfaction with informed consent and longitudinally evaluate the implementation of this intervention into clinical practice using the <underline>R</underline>each, <underline>E</underline>ffectiveness, <underline>A</underline>doption, <underline>I</underline>mplementation and <underline>M</underline>aintenance framework.</p>
                </sec>
                <sec>
                  <title>Ethics and dissemination</title>
                  <p>This study will create a model for <italic toggle="yes">APOL1</italic> testing of LDs of African ancestry, which can be implemented nationally via implementation science approaches. <italic toggle="yes">APOL1</italic> will serve as a model for integrating culturally competent genetic testing into transplant and other practices to improve informed consent. This study involves human participants and was approved by Northwestern University IRB (STU00214038). Participants gave informed consent to participate in the study before taking part.</p>
                </sec>
                <sec>
                  <title>Trial registration</title>
                  <p>ClinicalTrials.gov Identifier: <ext-link xlink:href="NCT04910867" ext-link-type="ClinicalTrials.gov" specific-use="clinicaltrial results">NCT04910867</ext-link>. Registered 8 May 2021, <ext-link xlink:href="https://register.clinicaltrials.gov/prs/app/action/SelectProtocol?sid=S000AWZ6&amp;selectaction=Edit&amp;uid=U0001PPF&amp;ts=7&amp;cx=-8jv7m2" ext-link-type="uri">https://register.clinicaltrials.gov/prs/app/action/SelectProtocol?sid=S000AWZ6&amp;selectaction=Edit&amp;uid=U0001PPF&amp;ts=7&amp;cx=-8jv7m2</ext-link>
</p>
                  <p>ClinicalTrials.gov Identifier: <ext-link xlink:href="NCT04999436" ext-link-type="ClinicalTrials.gov" specific-use="clinicaltrial results">NCT04999436</ext-link>. Registered 5 November 2021, <ext-link xlink:href="https://register.clinicaltrials.gov/prs/app/action/SelectProtocol?sid=S000AYWW&amp;selectaction=Edit&amp;uid=U0001PPF&amp;ts=11&amp;cx=9tny7v" ext-link-type="uri">https://register.clinicaltrials.gov/prs/app/action/SelectProtocol?sid=S000AYWW&amp;selectaction=Edit&amp;uid=U0001PPF&amp;ts=11&amp;cx=9tny7v</ext-link>
</p>
                </sec>
              </abstract>
              <kwd-group>
                <kwd>ETHICS (see Medical Ethics)</kwd>
                <kwd>GENETICS</kwd>
                <kwd>Organisation of health services</kwd>
                <kwd>End stage renal failure</kwd>
                <kwd>Renal transplantation</kwd>
                <kwd>QUALITATIVE RESEARCH</kwd>
              </kwd-group>
              <funding-group specific-use="FundRef">
                <award-group id="funding-1">
                  <funding-source>
                    <institution-wrap>
                      <institution>Alliance for Research in Chicagoland Communities/Northwestern University Clinical &amp; Translational Sciences Institute</institution>
                    </institution-wrap>
                  </funding-source>
                  <award-id>N/A</award-id>
                </award-group>
                <award-group id="funding-2">
                  <funding-source>
                    <institution-wrap>
                      <institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/100000062</institution-id>
                      <institution>National Institute of Diabetes and Digestive and Kidney Diseases</institution>
                    </institution-wrap>
                  </funding-source>
                  <award-id>1R01DK128207</award-id>
                </award-group>
                <award-group id="funding-3">
                  <funding-source>
                    <institution-wrap>
                      <institution>Northwestern Medicine Dixon Translational Research Innovation Award</institution>
                    </institution-wrap>
                  </funding-source>
                  <award-id>N/A</award-id>
                </award-group>
              </funding-group>
              <custom-meta-group>
                <custom-meta>
                  <meta-name>special-feature</meta-name>
                  <meta-value>unlocked</meta-value>
                </custom-meta>
              </custom-meta-group>
            </article-meta>
          </front>
          <body>
            <boxed-text id="BX1" position="float">
              <caption>
                <title>STRENGTHS AND LIMITATIONS OF THIS STUDY</title>
              </caption>
              <list list-type="bullet">
                <list-item>
                  <p>The type II hybrid study design enables simultaneous evaluation of the intervention and the implementation of the intervention with a coequal focus.</p>
                </list-item>
                <list-item>
                  <p>Participating centres’ location in different geographic regions enhances generalisability.</p>
                </list-item>
                <list-item>
                  <p>Study sites agreed to the same overall workflows and study protocol.</p>
                </list-item>
                <list-item>
                  <p>The <italic toggle="yes">Apolipoprotein</italic> L1 implementation process will be standardised by disseminating protocols, scripts and materials to both sites to ensure fidelity to the intervention and its delivery.</p>
                </list-item>
                <list-item>
                  <p>A limitation is that the study does not use DNA testing to assess living donors’ ancestry; however, DNA testing is not consistent across labs and would be cost-prohibitive.</p>
                </list-item>
              </list>
            </boxed-text>
            <sec id="s1">
              <title>Background</title>
              <p>Living donor (LD) kidney transplantation is the optimal treatment for patients with kidney failure,<xref rid="R1" ref-type="bibr">1 2</xref> with greater patient and graft survival and quality of life than deceased donor transplantation<xref rid="R3" ref-type="bibr">3 4</xref> or dialysis.<xref rid="R5" ref-type="bibr">5 6</xref> Patients of African ancestry have disproportionately greater rates of chronic kidney disease (CKD) and kidney failure compared with White patients. They also comprise disproportionately greater representation on the transplant waitlist but receive fewer transplants than White patients.<xref rid="R7" ref-type="bibr">7 8</xref> The estimated risk of kidney failure at 15 years post-donation is higher in LDs of African ancestry than in White LDs: 74.7 versus 22.7 per 10 000 LDs.<xref rid="R9" ref-type="bibr">9 10</xref> These findings have intensified the transplant field’s concerns with protecting LD safety, improving LD informed consent and reducing LD disparities in post-donation kidney disease.<xref rid="R11" ref-type="bibr">11–13</xref> LD, clinician and health system factors contribute to this disparity for LDs,<xref rid="R14" ref-type="bibr">14 15</xref> along with systemic racism and social determinants of health. In addition, the higher prevalence of CKD among patients of African ancestry compared with White patients has been attributed to <italic toggle="yes">Apolipoprotein L1</italic> or ‘<italic toggle="yes">APOL1’</italic> risk variants,<xref rid="R16" ref-type="bibr">16</xref> which are found predominantly in individuals of African ancestry.<xref rid="R16" ref-type="bibr">16–18</xref> Among patients of African ancestry <italic toggle="yes">without</italic> CKD, 13%–15% have two <italic toggle="yes">APOL1</italic> risk variants, and 39% have one risk variant.<xref rid="R10" ref-type="bibr">10 19</xref> Having two <italic toggle="yes">APOL1</italic> risk variants is associated with a 10-fold greater odds of focal segmental glomerulosclerosis-attributed kidney failure.<xref rid="R16" ref-type="bibr">16</xref> More than 3 million individuals of African ancestry in the USA are estimated to have two risk variants.<xref rid="R20" ref-type="bibr">20</xref> Kidneys from deceased donors with two <italic toggle="yes">APOL1</italic> risk variants had significantly greater risk of graft failure (two-fold HR) in recipients than kidneys from deceased donors with ≤1 variant.<xref rid="R21" ref-type="bibr">21 22</xref> Young male LDs of African ancestry with two <italic toggle="yes">APOL1</italic> risk variants were at highest risk of CKD post-donation compared with female and European American LDs.<xref rid="R23" ref-type="bibr">23</xref>
</p>
              <sec id="s1-1">
                <title>The research-to-practice gap</title>
                <p>The 2017 KDIGO Clinical Practice Guideline on the Evaluation and Care of Living Kidney Donors advises ‘…considering <italic toggle="yes">APOL1</italic> genotyping in LD candidates with sub-Saharan African ancestors’,<xref rid="R24" ref-type="bibr">24 25</xref> given that <italic toggle="yes">APOL1</italic> risk variants evolved in this region. The American Society of Transplantation in 2015 reported that current data were insufficient to support testing all LD candidates of African ancestry due to the lack of long-term population-level data on <italic toggle="yes">APOL1</italic> risk variants<xref rid="R25" ref-type="bibr">25</xref> and the lack of <italic toggle="yes">APOL1’s</italic> specificity in predicting disease.<xref rid="R26" ref-type="bibr">26 27</xref>
<italic toggle="yes">APOL1</italic> testing is controversial because of the lack of definitive evidence on the causal link between <italic toggle="yes">APOL1</italic> risk variants and LDs’ health outcomes, and the consequent ethical dilemmas raised, as described below. Thus, some physicians are waiting for results from the NIH-funded APOLLO study before implementing <italic toggle="yes">APOL1</italic> testing into their clinical practice.<xref rid="R28" ref-type="bibr">28</xref> Others posit that LDs of African ancestry should be screened for <italic toggle="yes">APOL1</italic> variants to risk stratify LDs; the presence of two risk variants should comprise a relative contraindication to donation requiring careful counselling and consent of LDs.<xref rid="R1" ref-type="bibr">1 26</xref>
</p>
                <p><italic toggle="yes">APOL1</italic> testing of LDs raises the ethical dilemma of whether to permit LDs of African ancestry with two <italic toggle="yes">APOL1</italic> risk variants to donate.<xref rid="R29" ref-type="bibr">29 30</xref> Donating could place such LDs at even greater harm, thereby challenging: (a) the ethical principle of non-maleficence as LDs gain no direct medical benefit from donation<xref rid="R31" ref-type="bibr">31 32</xref> and (b) the ethical justification for living donation: when ‘benefits to both the donor and the recipient outweigh the risks associated with the donation and transplantation’.<xref rid="R33" ref-type="bibr">33</xref> Not allowing LDs of African ancestry with two risk variants to donate could protect their safety by reducing their risk of CKD, but not donating could exacerbate disparities in access to LD transplantation for candidates of African ancestry and reduce patient survival.<xref rid="R26" ref-type="bibr">26 34</xref>
</p>
                <p>Genetic counselling and shared decision making (SDM) about undergoing <italic toggle="yes">APOL1</italic> genetic testing and living donation with <italic toggle="yes">APOL1</italic> risk variants are especially warranted given that donating is a preference-sensitive decision and <italic toggle="yes">APOL1</italic> poses elevated risks for LDs.<xref rid="R35" ref-type="bibr">35</xref> Transplant physicians are increasingly adopting <italic toggle="yes">APOL1</italic> testing,<xref rid="R36" ref-type="bibr">36 37</xref> but they do not consistently inform LD candidates about <italic toggle="yes">APOL1</italic> genetic testing, perform genetic counselling or practice SDM with LDs.<xref rid="R36" ref-type="bibr">36–39</xref> This variation results partly from physicians’ lack of practical knowledge and skills in <italic toggle="yes">APOL1</italic> counselling, and fear that <italic toggle="yes">APOL1</italic> testing will deter LDs from donating, which would further exacerbate African American transplant candidates’ disparities in access to LD kidney transplantation.<xref rid="R30" ref-type="bibr">30 36</xref>
</p>
                <p>Genetic counselling is ‘the process of helping people understand and adapt to the medical, psychological and familial implications of genetic contributions to disease’.<xref rid="R40" ref-type="bibr">40</xref> Counselling involves education about inheritance, testing and prevention to promote informed choices and includes SDM.<xref rid="R40" ref-type="bibr">40</xref> Counselling is effective in reducing decisional conflict, increasing knowledge and improving accuracy of risk perception,<xref rid="R41" ref-type="bibr">41</xref> which improve informed consent. Importantly, while LDs are usually eager to donate to improve family or friends’ health, many are uncertain about donating.<xref rid="R42" ref-type="bibr">42–46</xref> Concerns about long-term health conditions after donation were a reason for LDs’ reluctance to donate among 34% of potential donors (n=53) participating in in-depth interviews in a study in the Netherlands<xref rid="R42" ref-type="bibr">42</xref> and among 40% of LDs (n=174) in a retrospective US survey study.<xref rid="R45" ref-type="bibr">45</xref> Although most (87%) LDs of African ancestry in an interview study (n=23) expressed willingness to undergo <italic toggle="yes">APOL1</italic> testing, fewer (61%) would have donated if they had two risk variants.<xref rid="R47" ref-type="bibr">47</xref> In addition, most interviewed LDs of African ancestry (81%) ‘strongly agreed’ or ‘agreed’ that <italic toggle="yes">APOL1</italic> test results would have helped them decide whether to donate.<xref rid="R47" ref-type="bibr">47</xref> Most LDs of African ancestry (82%) in a focus group study (n=17) also would have wanted to receive genetic counselling about <italic toggle="yes">APOL1</italic> testing during LD evaluation.<xref rid="R48" ref-type="bibr">48</xref> Thus, <italic toggle="yes">APOL1</italic> risks may magnify LDs’ decisional conflict about donating,<xref rid="R47" ref-type="bibr">47</xref> which, as a prospective survey study of potential donors (n=53) in Taiwan found, is significantly associated with LDs’ lower likelihood to actually donate.<xref rid="R43" ref-type="bibr">43</xref> However, no studies have trained transplant physicians on <italic toggle="yes">APOL1</italic> genetics, counselling and race and prospectively assessed the impact of <italic toggle="yes">APOL1</italic> testing and counselling on LDs’ donation decisions.</p>
                <p>Barriers to the clinical integration of genomic testing include: providers’ lack knowledge and preparedness to provide genetic services;<xref rid="R49" ref-type="bibr">49–52</xref> healthcare systems do not enable electronic health records (EHRs) to make readily accessible genetic test results;<xref rid="R51" ref-type="bibr">51 53 54</xref> and clinical practice guidelines advise <italic toggle="yes">APOL1</italic> testing LDs of African ancestry but do not specify how to ascertain ancestry.<xref rid="R24" ref-type="bibr">24</xref> ‘Race’-based care or ‘racialised medicine’ conflates the outmoded social construction of ‘race’ as biological differences between groups of people with the genetic concept of ancestry<xref rid="R48" ref-type="bibr">48</xref> and reinforces racism to the detriment of the health of individuals of African ancestry.<xref rid="R55" ref-type="bibr">55</xref>
</p>
                <p>Systemic racism adversely affects health outcomes and contributes to health disparities across multiple levels of influence (eg, individual, interpersonal, community, societal) among multiple domains of influence (biological, behavioural, physical, sociocultural, healthcare system).<xref rid="R56" ref-type="bibr">56 57</xref> In the organ transplant context, numerous forms of systemic barriers exist across all levels and domains of influence, including: limited access to insurance coverage for transplantation, providers’ poor-quality communication about and limited referral to transplantation, and transplant allocation policies. Such systemic barriers have contributed to disproportionately lower rates of organ transplantation among African American patients and other minoritised patients.<xref rid="R58" ref-type="bibr">58 59</xref>
</p>
                <p>Genetic testing is one factor that can potentially contribute to systemic racism in transplantation and in other clinical contexts. Genetic testing can potentially exacerbate or mitigate systemic racism. On one hand, genetic testing can magnify systemic racism if it is not offered in an equitable way to all patients. At the individual level, many individuals of African ancestry hold cultural concerns about genetic testing (eg, beliefs and concerns about misuse of testing, mistrust in the medical system)<xref rid="R60" ref-type="bibr">60 61</xref> and fear that <italic toggle="yes">APOL1</italic> test results would lead to psychological distress, stigmatisation of the community of African ancestry and health insurance discrimination.<xref rid="R47" ref-type="bibr">47 62 63</xref> On the other hand, preparing the transplant provider workforce to offer <italic toggle="yes">APOL1</italic> genetic testing to all LDs of African ancestry and to provide genetic counselling in a culturally appropriate manner can help to reduce inequities by eliminating provider bias, acknowledging historical distrust of institutions and fostering trust. Culturally competent care can increase knowledge among people of African ancestry about donation<xref rid="R64" ref-type="bibr">64</xref> and LD rates.<xref rid="R65" ref-type="bibr">65</xref>
</p>
              </sec>
              <sec id="s1-2">
                <title>Study aims</title>
                <p><bold>Aim 1. Adapt Gia and transplant counselling to</bold><italic toggle="yes"><bold>APOL1</bold></italic><bold>for use in routine clinical practice</bold>. We will adapt a chatbot, Gia® (Genetic Information Assistant), and nephrologist counselling to ensure that they are culturally targeted and competent,<xref rid="R66" ref-type="bibr">66</xref> by engaging communities of African ancestry and experts in genetics, transplantation and bioethics. The goal of the adaptation process is to ensure implementation of the genetic testing and counselling components on a broad scale with minimal disruption to provider workflow.</p>
                <p><bold>Aim 2. Evaluate the effectiveness of this intervention on decisional conflict, preparedness and willingness to donate in a two-site, non-randomised, pre–post trial design</bold>. We hypothesise the intervention will:</p>
                <p>H<sub>1</sub>: decrease LDs’ decisional conflict about donation.</p>
                <p>H<sub>2</sub>: increase LDs’ preparedness for decision-making about donation.</p>
                <p>H<sub>3</sub>: not decrease LDs’ willingness to donate.</p>
                <p>
                  <bold>Aim 3. Evaluate the implementation of this intervention into clinical practice by using the RE-AIM framework to longitudinally evaluate nephrologist counselling practices and LDs’ satisfaction with informed consent</bold>
                </p>
                <p>We will use the <underline>R</underline>each, <underline>E</underline>ffectiveness, <underline>A</underline>doption, <underline>I</underline>mplementation and <underline>M</underline>aintenance (RE-AIM) framework to longitudinally evaluate implementation outcomes (ie, acceptability, appropriateness, feasibility, reach, adoption and fidelity).<xref rid="R67" ref-type="bibr">67</xref> We hypothesise implementation will:</p>
                <p>H<sub>4</sub>: increase nephrologists’ knowledge and skill in delivering counselling for <italic toggle="yes">APOL1</italic> testing and donation.</p>
                <p>H<sub>5</sub>: increase LDs’ satisfaction with informed consent about donation.</p>
              </sec>
            </sec>
            <sec sec-type="methods" id="s2">
              <title>Methods</title>
              <sec id="s2-1">
                <title>Overview and rationale for the study design</title>
                <p>Because genetic testing and chatbots are effective interventions, scientific focus can be shifted towards the implementation of genetic testing and the chatbot for <italic toggle="yes">APOL1</italic> and LDs of African ancestry.<xref rid="R68" ref-type="bibr">68</xref> The non-randomised clinical trial, with a pre–post implementation evaluation, uses a type II effectiveness–implementation hybrid approach to simultaneously and rigorously test a prospective implementation strategy during an effectiveness trial to facilitate translation into clinical practice.<xref rid="R69" ref-type="bibr">69 70</xref> Accordingly, control arm participants will be recruited during the preimplementation period, and intervention arm participants will be recruited during the postimplementation period.</p>
              </sec>
              <sec id="s2-2">
                <title>Study sites</title>
                <p>The proposed study will be conducted at Northwestern University (Chicago, IL) and Georgetown University (Washington, DC). Both transplant programmes have a large number of Black/African American LDs and are in cities with large populations of Black/African American people (30%-Chicago, 47%-DC).<xref rid="R71" ref-type="bibr">71</xref> Neither site systematically identifies the African ancestry of LDs or has a policy on LD selection for <italic toggle="yes">APOL1</italic> testing. Neither site uses SDM to aid in donation decisions.</p>
              </sec>
              <sec id="s2-3">
                <title><italic toggle="yes">APOL1</italic> genetic testing and counselling programmes</title>
                <sec id="s2-3-1">
                  <title><italic toggle="yes">APOL1</italic> genetic testing</title>
                  <list list-type="order">
                    <list-item>
                      <p><underline>Asking all LD candidates about their ancestry</underline>: asking all LDs about their ancestry will include LDs with African ancestry who might otherwise be missed.<xref rid="R48" ref-type="bibr">48</xref> This approach coincides with a pan-ethnic genetic screening paradigm<xref rid="R72" ref-type="bibr">72</xref> and avoids reinforcing the phenotype-based construct of ‘race’ for selecting LDs for <italic toggle="yes">APOL1</italic> testing.</p>
                    </list-item>
                    <list-item>
                      <p><underline>Offering <italic toggle="yes">APOL1</italic> genetic testing to all LD candidates with African ancestry</underline> that pass initial screening; half of LD candidates do not pass.<xref rid="R73" ref-type="bibr">73</xref> Testing LDs early avoids unnecessary expense of other tests for LDs who will be ruled out.<xref rid="R47" ref-type="bibr">47 74</xref>
<italic toggle="yes">APOL1</italic> genotyping all LD candidates of African ancestry is cost-effective in preventing CKD.<xref rid="R75" ref-type="bibr">75</xref>
</p>
                    </list-item>
                  </list>
                </sec>
                <sec id="s2-3-2">
                  <title><italic toggle="yes">APOL1</italic> genetic counselling</title>
                  <list list-type="order">
                    <list-item>
                      <p><italic toggle="yes">A clinical chatbot will provide pre-APOL1 genetic testing information</italic> based on LDs’ information needs.<xref rid="R47" ref-type="bibr">47</xref> Chatbots increase informed treatment decisions and reduce decisional conflict.<xref rid="R76" ref-type="bibr">76 77</xref> This study will create the first chatbot on <italic toggle="yes">APOL1</italic>.</p>
                    </list-item>
                    <list-item>
                      <p><italic toggle="yes">Nephrologists will provide post-APOL1 counselling</italic> about test results to normalise <italic toggle="yes">APOL1</italic> in the routine LD evaluation process (<xref rid="T1" ref-type="table">table 1</xref>). Nephrologists will engage in SDM with LDs who test positive for two risk variants about donating, as recommended.<xref rid="R78" ref-type="bibr">78</xref>
</p>
                    </list-item>
                    <list-item>
                      <p><italic toggle="yes">A culturally competent educational brochure</italic> on <italic toggle="yes">APOL1</italic> that our team previously developed will be given by nephrologists to LD candidates of African ancestry during evaluation and be available in the transplant centre waiting room.<xref rid="R48" ref-type="bibr">48</xref>
</p>
                    </list-item>
                  </list>
                  <table-wrap position="float" id="T1">
                    <label>Table 1</label>
                    <caption>
                      <p><italic toggle="yes">APOL1</italic> counselling training programme content domains</p>
                    </caption>
                    <table frame="hsides" rules="groups">
                      <thead>
                        <tr>
                          <td align="left" valign="bottom" rowspan="1" colspan="1">Module</td>
                          <td align="left" valign="bottom" rowspan="1" colspan="1">Description: after completing the training, nephrologists will be able to…</td>
                        </tr>
                      </thead>
                      <tbody>
                        <tr>
                          <td align="left" valign="top" rowspan="1" colspan="1">Introduction</td>
                          <td align="left" valign="top" rowspan="1" colspan="1">Articulate the programme’s purpose and who it is designed to help</td>
                        </tr>
                        <tr>
                          <td align="left" valign="top" rowspan="1" colspan="1"><italic toggle="yes">APOL1</italic> and kidney disease</td>
                          <td align="left" valign="top" rowspan="1" colspan="1">Define <italic toggle="yes">APOL1</italic> and its relationship to kidney disease</td>
                        </tr>
                        <tr>
                          <td align="left" valign="top" rowspan="1" colspan="1"><italic toggle="yes">APOL1</italic>: risks, benefits and limitations of living kidney donation and genetic testing to living donors, their family and their recipients</td>
                          <td align="left" valign="top" rowspan="1" colspan="1">Describe the risks of having two risk variants on LDs’ post-donation health, their reproduction and on other family members; communicate about genetic risks as modifiable vs non-modifiable</td>
                        </tr>
                        <tr>
                          <td align="left" valign="top" rowspan="1" colspan="1">Genetic variation and ‘Race’: knowledge and practice</td>
                          <td align="left" valign="top" rowspan="1" colspan="1">Communicate about <italic toggle="yes">APOL1</italic> and address the values and beliefs among people of African ancestry about genetic testing in a culturally and socially sound manner</td>
                        </tr>
                        <tr>
                          <td align="left" valign="top" rowspan="1" colspan="1">Access, insurance, privacy, and confidentiality of testing and test results</td>
                          <td align="left" valign="top" rowspan="1" colspan="1">Explain how LDs’ privacy and confidentiality of test results will be protected; the limits of the Genetic Information Nondiscrimination Act of 2008; what will happen to test results, and who has access to them</td>
                        </tr>
                        <tr>
                          <td align="left" valign="top" rowspan="1" colspan="1">Ethics</td>
                          <td align="left" valign="top" rowspan="1" colspan="1">Compare ethical implications of donating and not donating</td>
                        </tr>
                        <tr>
                          <td align="left" valign="top" rowspan="1" colspan="1">Shared decision-making</td>
                          <td align="left" valign="top" rowspan="1" colspan="1">Engage in SDM with LD candidates with two risk variants about donating; explain the relative benefit to recipients of LDKT vs staying on dialysis</td>
                        </tr>
                        <tr>
                          <td align="left" valign="top" rowspan="1" colspan="1">Case study discussion</td>
                          <td align="left" valign="top" rowspan="1" colspan="1">Apply concepts learnt in modules to an actual case.</td>
                        </tr>
                      </tbody>
                    </table>
                    <table-wrap-foot>
                      <fn id="T1_FN1">
                        <p><italic toggle="yes">APOL1</italic>, Apolipoprotein L1; LD, living donor; LDKT, Living Donor Kidney Transplantation; SDM, shared decision-making.</p>
                      </fn>
                    </table-wrap-foot>
                  </table-wrap>
                </sec>
              </sec>
              <sec id="s2-4">
                <title>Implementation strategies</title>
                <p>We will use several implementation strategies to accomplish the study’s aims,<xref rid="R79" ref-type="bibr">79</xref>multiple methods to document them<xref rid="R80" ref-type="bibr">80</xref> and the Implementation Research Logic Model<xref rid="R81" ref-type="bibr">81 82</xref> (<xref rid="F1" ref-type="fig">figure 1</xref>) to specify the conceptual associations between determinants, strategies and the hypothesised/observed mechanisms and outcomes that result. The Implementation Research Logic Model (IRLM) provides a comprehensive set of strategies to be used. The following strategies are the primary focus of the study: establishing academic–community partnership, leveraging a Community Advisory Board (CAB), engaging patients, using a chatbot, educating and training transplant nephrologists, integration of genetic testing into the EHR and financing <italic toggle="yes">APOL1</italic> testing. Additional details on each of the primary strategies are available in <xref rid="SP1" ref-type="supplementary-material">online supplemental file 1</xref> and <xref rid="SP2" ref-type="supplementary-material">online supplemental file 2</xref>.</p>
                <supplementary-material id="SP1" position="float" content-type="local-data">
                  <object-id pub-id-type="doi">10.1136/bmjopen-2022-067657.supp1</object-id>
                  <label>Supplementary data</label>
                  <p>
                    <inline-supplementary-material id="SS1" xlink:href="bmjopen-2022-067657supp001.pdf" content-type="local-data"/>
                  </p>
                </supplementary-material>
                <supplementary-material id="SP2" position="float" content-type="local-data">
                  <object-id pub-id-type="doi">10.1136/bmjopen-2022-067657.supp2</object-id>
                  <label>Supplementary data</label>
                  <p>
                    <inline-supplementary-material id="SS2" xlink:href="bmjopen-2022-067657supp002.pdf" content-type="local-data"/>
                  </p>
                </supplementary-material>
                <fig position="float" id="F1">
                  <label>Figure 1</label>
                  <caption>
                    <p>Implementation research logic model. <italic toggle="yes">APOL1,</italic> Apolipoprotein L1; LD, living donor; NU, Northwestern University; GU, Georgetown University; CSAT, Clinical Sustainability Assessment Tool; RACE, Racial Attributes in Clinical Evaluation. Determinants are rated using Damschroder et al.’s (2013) coding system of the relative strength on a scale from –2 (strong negative impact), –1 (weak negative impact), 0 (neutral or mixed influence), 1 (weak positive impact), 2 (strong positive impact). Determinants are separated with a forward slash (/) to indicate ratings from each site (Northwestern/Georgetown). Superscripted letters indicate conceptual relationships between elements of the model ending with the implementation outcome. Note that not all determinants have an associated implementation strategy and not all strategies have a hypothesized mechanism; emphasis was placed on the causal paths associated with the study aims and hypotheses.</p>
                  </caption>
                  <graphic xlink:href="bmjopen-2022-067657f01" position="float"/>
                </fig>
              </sec>
              <sec id="s2-5">
                <title>Patient and public involvement</title>
                <p>We established a CAB comprised of transplant patients and community leaders who provided input on the study design, outcome measures, informed consent and recruitment and retention procedures. The CAB will review study results to provide insights into interpretation and foster dissemination.</p>
              </sec>
              <sec id="s2-6">
                <title>Assessment strategy, measures and data analysis</title>
                <sec id="s2-6-1">
                  <title><italic toggle="yes">APOL1</italic> intervention</title>
                  <p>The <italic toggle="yes">APOL1</italic> testing programme has been designed to fit within the routine LD evaluation process of the two sites, which limits LD clinic visits to 1 day. LDs will have four touchpoints of data collection (<xref rid="T2" ref-type="table">table 2</xref>). Between the labs (eg, blood, EKG, CT) and nephrology visit, research staff will screen all LDs by asking the 3 ancestry screening questions, obtain informed consent for study participation, conduct baseline surveys and provide the chatbot link to use for 5–7 min (<bold>T1</bold>). Tablets will be provided if LDs do not have a smartphone. The three ancestry questions include: ‘What ethnic/racial groups do you identify with?’ (eligible for study: Black, African American, Jamaican, Barbadian, Grenadian, Brazilian from Salvador, Trinidadian, Panamanian, Honduran, Haitian, Garifunan, Palenque, Guyanese, Dominican, Peruvian, Belizean and Native American); ‘Are you aware of any biologically-related family with African ancestry?’ and ‘What is your ancestry?’.<xref rid="R83" ref-type="bibr">83 84</xref> After LDs meet with the nephrologist, staff will ask for informed consent for <italic toggle="yes">APOL1</italic> testing, collect a saliva sample and mail it to the laboratory. Research staff call LDs a week later to qualitatively assess LDs’ perceptions of the chatbot, and its impact on outcome measures (<bold>T2</bold>). Clinical decision support in the EHR will alert the nephrologists when <italic toggle="yes">APOL1</italic> test results return and will prompt the nephrologists to call LDs to discuss the <italic toggle="yes">APOL1</italic> test results and engage in SDM about donation. Research staff will call LDs 1–2 business days thereafter to qualitatively assess LDs’ perceptions of the counselling and its impact on outcome measures (<bold>T3</bold>). Research staff will call LDs 1 month after donating/rule out for donation (eg, medical, surgical, psychological) to assess decisional regret (<bold>T4</bold>). During year 1, which serves as the preimplementation control phase, both sites will only assess T1 and T4 LD outcomes.</p>
                  <table-wrap position="float" id="T2">
                    <label>Table 2</label>
                    <caption>
                      <p>Intervention measures collected across time (T)</p>
                    </caption>
                    <table frame="hsides" rules="groups">
                      <tbody>
                        <tr>
                          <td align="left" valign="bottom" rowspan="6" colspan="1">
                            <bold>Independent measures</bold>
                          </td>
                          <td align="left" valign="bottom" rowspan="1" colspan="1">Sociodemographics including age, gender, marital status, education, income level,<xref rid="R114" ref-type="bibr">114</xref> self-identified racial and ethnic identities,<xref rid="R115" ref-type="bibr">115 116</xref> and one validated health literacy item.<xref rid="R117" ref-type="bibr">117</xref>
</td>
                        </tr>
                        <tr>
                          <td align="left" valign="bottom" rowspan="1" colspan="1">Relationship between LD and recipient: directed (spouse, parent, adult child, sibling, friend, etc.) vs non-directed donor.</td>
                        </tr>
                        <tr>
                          <td align="left" valign="bottom" rowspan="1" colspan="1">Smartphone ownership and use: will be assessed by two yes/no questions for example, ‘Do you already have a working “smartphone”-capable cellular device (Internet capable)’?<xref rid="R118" ref-type="bibr">118</xref>
</td>
                        </tr>
                        <tr>
                          <td align="left" valign="bottom" rowspan="1" colspan="1">Knowledge of genetics will be assessed by nine true/false items from validated surveys.<xref rid="R119" ref-type="bibr">119 120</xref>
</td>
                        </tr>
                        <tr>
                          <td align="left" valign="bottom" rowspan="1" colspan="1">Self-efficacy with genetic information will measure LDs’ confidence and ability to understand and use genetic information in a 5-item Likert scale (α=0.92).<xref rid="R119" ref-type="bibr">119–121</xref>
</td>
                        </tr>
                        <tr>
                          <td align="left" valign="bottom" rowspan="1" colspan="1">Decision to undergo APOL1 genetic testing will be measured in two items: ‘Do you plan to get the APOL1 test’ or ‘Did you decide to get the APOL1 test?’ (yes/no)</td>
                        </tr>
                        <tr>
                          <td align="left" valign="top" rowspan="8" colspan="1">
                            <bold>Outcome measures</bold>
                          </td>
                          <td align="left" valign="top" rowspan="1" colspan="1">Decisional Conflict Scale (DCS)<xref rid="R122" ref-type="bibr">122 123</xref> will measure perceived uncertainty in decision-making about donating and satisfaction with effective decision-making, and nephrologists’ decision-making before and after genetic counselling. The revised DCS includes 16 items organised into to a Total score and Uncertainty, Informed, Values Clarity, Support and Effective Decision subscores measured on a 5-point Likert scale.<xref rid="R123" ref-type="bibr">123</xref> Test–retest reliability coefficient=0.81. Internal consistency coefficients=0.78–0.92.<xref rid="R122" ref-type="bibr">122 124</xref> It takes 3 min to complete.</td>
                        </tr>
                        <tr>
                          <td align="left" valign="top" rowspan="1" colspan="1">Preparation for Decision Making Scale (PDMS) is a process measure that will assess LDs’ perception of how useful the chatbot and counselling is in preparing them to communicate with their physician and make the donation decision. PDMS includes 10 items measured on a 5-point scale.<xref rid="R125" ref-type="bibr">125</xref> Cronbach’s α ranged from 0.92 to 0.96.</td>
                        </tr>
                        <tr>
                          <td align="left" valign="top" rowspan="1" colspan="1">Willingness to Donate will be measured in one 10-point Likert item, as used elsewhere.<xref rid="R14" ref-type="bibr">14</xref>
</td>
                        </tr>
                        <tr>
                          <td align="left" valign="top" rowspan="1" colspan="1">Decision Chosen will be assessed via EHR review as donated/not donated.</td>
                        </tr>
                        <tr>
                          <td align="left" valign="top" rowspan="1" colspan="1">Perceptions of Culturally Competent Counseling will be assessed by 10 Likert items.<xref rid="R126" ref-type="bibr">126 127</xref>
</td>
                        </tr>
                        <tr>
                          <td align="left" valign="top" rowspan="1" colspan="1">Shared Decision Making (SDM-Q9) will assess SDM in nine items. Cronbach’s α=0.93.<xref rid="R128" ref-type="bibr">128</xref>
</td>
                        </tr>
                        <tr>
                          <td align="left" valign="top" rowspan="1" colspan="1">Satisfaction with the Informed Consent Process will be measured using 20 validated closed-ended questions that assess decision-making quality, decision satisfaction and perception of information.<xref rid="R129" ref-type="bibr">129 130</xref> It takes 4 min to complete.</td>
                        </tr>
                        <tr>
                          <td align="left" valign="top" rowspan="1" colspan="1">Decision Regret Scale (DRS)<xref rid="R131" ref-type="bibr">131</xref> will assess LDs’ level of regret with (not) donating, and with (not) undergoing APOL1 testing. DRS consists of 5 items, Cronbach’s α&gt;0.81–0.92.<xref rid="R131" ref-type="bibr">131</xref>
</td>
                        </tr>
                      </tbody>
                    </table>
                    <table-wrap-foot>
                      <fn id="T2_FN1">
                        <p><italic toggle="yes">APOL1</italic>, Apolipoprotein L1; EHR, electronic health record; LD, living donor.</p>
                      </fn>
                    </table-wrap-foot>
                  </table-wrap>
                </sec>
                <sec id="s2-6-2">
                  <title>Statistical analyses</title>
                  <p>Descriptive summaries will be generated for all data (eg, means and SD, medians, IQR and ranges for continuous data; counts and frequencies for categorical data). Graphical summaries (ie, histograms, boxplots) will be used to assess distribution shapes and evaluate transformations to improve normality. To evaluate potential differences in LD demographic and clinical characteristics before and after implementing the <italic toggle="yes">APOL1</italic> intervention, summary statistics will be compared for LDs in the control and intervention enrolment periods within each centre.</p>
                  <p>Analyses for <bold>H<sub>1</sub>
</bold> will employ a linear mixed effect model with fixed effects for arm (pre or postimplementation) and study period. The included random centre effect will allow for separation of within-centre and between-centre variance estimates. The primary outcome, decisional conflict, will be treated as a normal, continuous outcome (for discussion of power for the primary outcome, see <xref rid="SP3" ref-type="supplementary-material">online supplemental file 3</xref>). Modelling approaches will consider statistical adjustment for LD-level demographic and clinical characteristics, especially for characteristics that differ for LDs within a centre before and after implementation. Analyses will be performed under an intent-to-treat framework. Analyses for <bold>H<sub>2</sub>
</bold> and <bold>H<sub>5</sub>
</bold> will employ similar methods for preparedness for decision-making and satisfaction with informed consent, respectively. Analyses for <bold>H<sub>3</sub>
</bold> will be conducted under a non-inferiority framework. Specifically, we will estimate a CI for the difference in medians to compare the willingness to donate between the preimplementation and implementation periods. If the lower limit of a two-sided 95% CI is within the margin of non-inferiority, we will have evidence that the <italic toggle="yes">APOL1</italic> counselling intervention does not meaningfully reduce the willingness to donate. We will assume a non-inferiority margin of 1.5 units, which reflects a negligible difference in scores. Young (age 35–44 years), male, LDs of African ancestry with <italic toggle="yes">APOL1</italic> risk variants have the highest risk of developing CKD, although most LDs are women.<xref rid="R23" ref-type="bibr">23 85</xref> Thus, planned subgroup analyses will consider assessment of LD outcomes by sex and age groups. These analyses will be deemed exploratory given power considerations.</p>
                  <supplementary-material id="SP3" position="float" content-type="local-data">
                    <object-id pub-id-type="doi">10.1136/bmjopen-2022-067657.supp3</object-id>
                    <label>Supplementary data</label>
                    <p>
                      <inline-supplementary-material id="SS3" xlink:href="bmjopen-2022-067657supp003.pdf" content-type="local-data"/>
                    </p>
                  </supplementary-material>
                </sec>
                <sec id="s2-6-3">
                  <title>Implementation of the <italic toggle="yes">APOL1</italic> testing programme into clinical practice</title>
                  <p>Assessment of determinants is focused on the inner and outer context variables of the Consolidated Framework for Implementation Research (CFIR).<xref rid="R86" ref-type="bibr">86</xref> Implementation evaluation follows the RE-AIM evaluation framework (<xref rid="T3" ref-type="table">table 3</xref>).<xref rid="R87" ref-type="bibr">87–90</xref> We will also test changes in knowledge and self-efficacy for genetic counselling among nephrologists as a hypothesised mechanism affecting their decision to adopt the <italic toggle="yes">APOL1</italic> counselling component of the intervention.</p>
                  <table-wrap position="float" id="T3">
                    <label>Table 3</label>
                    <caption>
                      <p>Measurement strategy for implementation outcomes</p>
                    </caption>
                    <table frame="hsides" rules="groups">
                      <thead>
                        <tr>
                          <td align="left" valign="bottom" rowspan="1" colspan="1"/>
                          <td align="left" valign="bottom" rowspan="1" colspan="1">Variable/construct</td>
                          <td align="left" valign="bottom" rowspan="1" colspan="1">Measure(s)/metrics</td>
                          <td align="left" valign="bottom" rowspan="1" colspan="1">Source</td>
                        </tr>
                      </thead>
                      <tbody>
                        <tr>
                          <td align="left" valign="top" rowspan="9" colspan="1">
                            <bold>RE-AIM Implementation Evaluation Framework</bold>
                          </td>
                          <td align="left" valign="top" rowspan="1" colspan="1">Reach</td>
                          <td align="left" valign="top" rowspan="1" colspan="1">Proportion of LD candidates attending clinic visit who were notified about being potentially eligible for genetic testing/counselling<break/>Proportion of enrolled LDs (study participants) who were scheduled by the nephrologist for post-test counselling</td>
                          <td align="left" valign="top" rowspan="1" colspan="1">Study data<break/>EHR</td>
                        </tr>
                        <tr>
                          <td align="left" valign="top" rowspan="1" colspan="1">Effectiveness (of the APOL1 intervention)</td>
                          <td align="left" valign="top" rowspan="1" colspan="1">Effect size of the APOL1 testing programme for LDs.</td>
                          <td align="left" valign="top" rowspan="1" colspan="1">
                            <xref rid="SP3" ref-type="supplementary-material">online supplemental file 3</xref>
                          </td>
                        </tr>
                        <tr>
                          <td align="left" valign="top" rowspan="1" colspan="1">Adoption</td>
                          <td align="left" valign="top" rowspan="1" colspan="1">Number and proportion of: 1) ordered <italic toggle="yes">APOL1</italic> genetic tests, 2) nephrologists who delivered <italic toggle="yes">APOL1</italic> post-test counselling, and 3) nephrologists who engaged in shared decision-making.<break/>Number and proportion of LDs who: 1) used the chatbot, 2) number of questions asked and/or information requests submitted, and 3) duration (minutes) of chatbot use.</td>
                          <td align="left" valign="top" rowspan="1" colspan="1">EHR<break/>Chatbot</td>
                        </tr>
                        <tr>
                          <td align="left" valign="top" colspan="3" rowspan="1">Implementation</td>
                        </tr>
                        <tr>
                          <td align="left" valign="top" rowspan="1" colspan="1"> a. Acceptability</td>
                          <td align="left" valign="top" rowspan="1" colspan="1">Acceptability of Intervention Measure (AIM)<xref rid="R93" ref-type="bibr">93</xref> 4 items (α=0.85)</td>
                          <td align="left" valign="top" rowspan="1" colspan="1">Survey</td>
                        </tr>
                        <tr>
                          <td align="left" valign="top" rowspan="1" colspan="1"> b. Appropriateness</td>
                          <td align="left" valign="top" rowspan="1" colspan="1">Intervention Appropriateness Measure (IAM)<xref rid="R93" ref-type="bibr">93</xref> 4 items (α=0.91)</td>
                          <td align="left" valign="top" rowspan="1" colspan="1">Survey</td>
                        </tr>
                        <tr>
                          <td align="left" valign="top" rowspan="1" colspan="1"> c. Feasibility</td>
                          <td align="left" valign="top" rowspan="1" colspan="1">Feasibility of Intervention Measure (FIM)<xref rid="R93" ref-type="bibr">93</xref> 4 items (α=0.89)</td>
                          <td align="left" valign="top" rowspan="1" colspan="1">Survey</td>
                        </tr>
                        <tr>
                          <td align="left" valign="top" rowspan="1" colspan="1"> d. Fidelity</td>
                          <td align="left" valign="top" rowspan="1" colspan="1">Direct observation (listening) and checklist assessment of counselling sessions<break/>Chatbot launch, questions asked/information sought, duration of chatbot use</td>
                          <td align="left" valign="top" rowspan="1" colspan="1">Observation<break/>Chatbot</td>
                        </tr>
                        <tr>
                          <td align="left" valign="top" rowspan="1" colspan="1">Sustainment</td>
                          <td align="left" valign="top" rowspan="1" colspan="1">Clinical Sustainability Assessment Tool<xref rid="R132" ref-type="bibr">132</xref> seven domains (three items each) (Engaged Leadership and Staff; Engaged Stakeholders; Planning and Implementation; Workflow Integration; Monitoring and Evaluation; Organisational Context and Capacity; Outcomes and Effectiveness). It is reliable, usable and valid in a pilot study (n=126) with internal consistencies ranging from (α=0.82–.89).<xref rid="R132" ref-type="bibr">132</xref>
</td>
                          <td align="left" valign="top" rowspan="1" colspan="1">Survey</td>
                        </tr>
                      </tbody>
                    </table>
                    <table-wrap-foot>
                      <fn id="T3_FN1">
                        <p>APOL1, Apolipoprotein L1; EHR, electronic health record; LD, living donor.</p>
                      </fn>
                    </table-wrap-foot>
                  </table-wrap>
                </sec>
                <sec id="s2-6-4">
                  <title>Determinants</title>
                  <p>We will conduct in-depth interviews<xref rid="R91" ref-type="bibr">91 92</xref> with nephrologists about their perceived facilitators, barriers, organisational capacity and adaptations to the <italic toggle="yes">APOL1</italic> testing programme using the CFIR interview guide (<ext-link xlink:href="www.cfirguide.org" ext-link-type="uri">www.cfirguide.org</ext-link>). Nephrologists will be interviewed before implementation, after implementation and before the implementation period ends. Interviews will be conducted in person or by phone by an experienced interviewer, last 30–45 min, and be audio-recorded.</p>
                </sec>
                <sec id="s2-6-5">
                  <title>Acceptability, appropriateness, and feasibility</title>
                  <p>We will conduct brief phone surveys to assess LDs’ and nephrologists’ perceptions of the <italic toggle="yes">APOL1</italic> testing and counselling programme using validated surveys<xref rid="R93" ref-type="bibr">93</xref> and standard methods<xref rid="R94" ref-type="bibr">94</xref> with LDs at T3 and T4. Nephrologists are surveyed after completing training but before enrolling LDs, after administering the <italic toggle="yes">APOL1</italic> intervention for 2 months and after 1 year.</p>
                </sec>
                <sec id="s2-6-6">
                  <title>Reach and adoption</title>
                  <p>We will calculate <underline>R</underline>each using study enrolment data using continuous 3-month sampling periods to closely approximate LDs counselled at any given point. We will use non-linear growth modelling approaches to examine rate of change in reach over time. Reach is also the proportion of LDs who consent and give saliva samples out of LDs offered <italic toggle="yes">APOL1</italic> testing. We expect to achieve an 80% reach rate at the centre level.<xref rid="R95" ref-type="bibr">95</xref> We will determine the representativeness of participants by comparing demographic characteristics between participants and non-participants.<xref rid="R96" ref-type="bibr">96</xref>
<underline>A</underline>doption is the number and proportion of nephrologists who deliver genetic counselling to ≥1 enrolled participant. We will assess whether nephrologists vary in offering counselling based on LD and nephrologist factors using analysis of covariance (ANCOVA) and multiple regression. Reach and adoption rates will be compared across centres using analysis of variance (ANOVA) and within-nephrologist using multilevel modelling techniques.</p>
                </sec>
                <sec id="s2-6-7">
                  <title>Fidelity</title>
                  <p>The extent to which the <italic toggle="yes">APOL1</italic> testing programme is delivered as intended will be assessed by: (1) nephrologist adherence to prescribed counselling behaviours and (2) adherence to the chatbot strategy. Because counselling occurs by telephone, research staff will be present to audio-record discussions, and thereafter listen to a random sample (50%) of sessions (in the control and intervention arms) using a standardised observer checklist<xref rid="R97" ref-type="bibr">97</xref> to document and evaluate the observed delivery and quality of prescribed counselling behaviours to generate a fidelity score.<xref rid="R98" ref-type="bibr">98 99</xref> We will compare fidelity across nephrologists (ANCOVA), across centres (ANOVA) and across time to test for drift (non-linear mixed model with time by nephrologist interaction). We will evaluate improvement in nephrologists’ counselling skills by comparing the fidelity between nephrologists counselling LDs in the control versus intervention arms, and by nephrologist sex/gender, using correlations and regressions. Few studies examine adaptations to interventions, which can affect fidelity.<xref rid="R88" ref-type="bibr">88</xref> We will track types of and reasons for adaptations using Stirman’s FRAME (Framework for Reporting Adaptations and Modifications-Enhanced)<xref rid="R100" ref-type="bibr">100</xref> via interviews with nephrologists as our team has done previously.<xref rid="R101" ref-type="bibr">101</xref> Chatbot fidelity metrics will include: number of LDs who launched the chatbot ≥1 time, number of questions asked or information requests submitted and duration (minutes) of use. We will assess whether the effects of the intervention (ie, LDs’ reduced decisional conflict, increased preparation) vary as a function of fidelity to the intervention (ie, nephrologist and chatbot metrics) using ANCOVA. We will treat EHR integration as an independent variable that may affect the implementation process. Because EHR integration is designed to most proximally support nephrologist behaviours of engaging in post-test counselling and performing SDM, we will examine site-level differences in EHR integration to understand quantitative differences in nephrologist fidelity metrics.</p>
                </sec>
                <sec id="s2-6-8">
                  <title>Sustainability</title>
                  <p>At the end of the implementation period, all nephrologists will complete the Clinical Sustainability Assessment Tool to assess preferences and perceptions of factors influencing intervention sustainability.<xref rid="R102" ref-type="bibr">102</xref> The seven domains (three items each) have good internal consistency (α range=0.84–0.92) and confirmatory factor analysis results demonstrated very good fit of the seven domain structure of the tool.<xref rid="R102" ref-type="bibr">102</xref>
</p>
                </sec>
                <sec id="s2-6-9">
                  <title>Increasing nephrologists’ knowledge and skills in APOL1 counselling</title>
                  <p>Increasing knowledge and self-efficacy in counselling skills is hypothesised to affect whether they adopt counselling, which will ultimately impact LDs’ outcomes. We will assess practical knowledge and self-efficacy before and after the <italic toggle="yes">APOL1</italic> counselling training programme via a 13-item survey, widely used in other provider counselling training programmes<xref rid="R103" ref-type="bibr">103 104</xref>; and surveys of beliefs about race (nine items)(α=0.61–0.69), attributes of race (eight items) (α=0.86) and genetic variation knowledge (eight items).<xref rid="R105" ref-type="bibr">105</xref>
<bold>H<sub>4</sub>
</bold> will be analysed by evaluating increases in practical knowledge and self-efficacy via a Wilcoxon signed-rank test to compare the survey scores on the pretest to the survey scores on the post-test. Due to sample size limitations, we will examine the relationship between changes in knowledge and skill with adoption in a separate analysis, rather than a formal test of mediation, to obtain parameter estimates to power a future study of this mechanistic path.</p>
                </sec>
                <sec id="s2-6-10">
                  <title>Qualitative data analysis</title>
                  <p>All audio-recorded focus groups (aim 1) and interviews (aim 2 and aim 3) will be transcribed and analysed for themes emergent from the data<xref rid="R106" ref-type="bibr">106 107</xref> using constant comparison<xref rid="R108" ref-type="bibr">108</xref> and inductive and deductive coding methods.<xref rid="R109" ref-type="bibr">109</xref> Initial codebooks will be developed by establishing deductive codes derived from moderator and interview guide questions. Through an iterative, constant comparative process, research staff will derive inductive codes emergent from the data to stay grounded in the respondent’s point of view by independently reviewing, comparing and openly coding the first set of five transcripts at each site. A series of retreats will be held, whereby staff will compare codes and resolve coding discrepancies in order to refine the codebook until reaching thematic saturation.<xref rid="R110" ref-type="bibr">110 111</xref> All transcripts will be independently coded using NVivo (QSR International) until reaching inter-rater reliability (Kappa &gt;0.80).<xref rid="R107" ref-type="bibr">107</xref> Thereafter, all transcripts will be independently coded by at least two research staff and any discrepancies in coding will be resolved through discussion. A summary of each theme will be written by reviewing and comparing all segments of text for a given code across participants/focus groups. Multiple coders and intercoder agreement checks will increase rigour and reliability of the codebook.<xref rid="R112" ref-type="bibr">112</xref> Qualitative data analysis software will aid in coding. We will increase the rigour and reproducibility of qualitative findings via: intermittent member checks with focus group (FG) participants, CAB members and nephrologists to obtain their feedback and verify accuracy of findings, thereby increasing credibility. Using thick description and an audit trail will increase dependability and transferability. Self-reflexivity and triangulation will increase confirmability.<xref rid="R113" ref-type="bibr">113</xref> Results from aim 2 and aim 3 interviews will be used to understand implementation processes and help contextualise aim 3 quantitative results.</p>
                </sec>
              </sec>
            </sec>
            <sec id="s3">
              <title>Current status and protocol modifications</title>
              <p>To date, we completed adaptation of the Gia chatbot, which involved conducting n=10 focus groups. We also completed adaptation of the <italic toggle="yes">APOL1</italic> counselling training programme and obtained approvals to provide Continuing Medical Education and Maintenance of Certification (MOC) credits to nephrologists partaking in the programme, which is anticipated to begin in July 2022. We began recruitment in September 2021 for the LD trial, and as of 13 May, we have obtained informed consent and enrolled n=60 LDs of African ancestry in the control arm. Despite a year of concerted meetings and efforts to identify ways to automate the integration of <italic toggle="yes">APOL1</italic> genetic test results directly into Epic, Epic policies pertaining to research and resource limitations at the laboratory prohibited this from occurring, requiring the uploading of faxed results by clinical staff. This change did not impact the research plan as transplant nephrologists still had a mechanism to review results in Epic.</p>
              <p>We made several protocol modifications since study inception. With regard to the chatbot, we designed Gia in English but not in Spanish given additional costs involved. Also, per focus group feedback to ensure ample time to complete it prior to the nephrologist visit, Gia would be delivered over 7–12 min rather than 5–7 min, as originally anticipated. We also adapted the educational brochure on <italic toggle="yes">APOL1</italic> for nephrologists to hand out to LDs based on updated empirical research and CAB feedback, which is available by request to the corresponding author. The <italic toggle="yes">APOL1</italic> counselling training programme did not undergo focus group evaluation because needs assessment interviews and team consultation sufficed to finalise programme content and format, as proposed. However, focus groups were conducted among nephrologists to assess their clinical decision support needs for optimal EHR integration.</p>
              <p>Regarding recruitment modifications, recruitment shifted to virtual then hybrid (virtual and in-person) at one site (Georgetown). Additionally, recruitment was slower than anticipated due to COVID-19, hiring delays, adapting the recruitment and implementation strategies to virtual recruitment, and IRB and contractual delays. Thus, the timeframe for launching the control arm was delayed by 2 months (Northwestern) and 5 months (Georgetown), and the intervention arm was delayed by 2 months (both sites).</p>
              <p>Regarding data collection modifications, both nephrologist pretest and post-test counselling discussions with LDs are recorded for LD participants in the control and intervention arms to enable a direct comparison between them due to using an identical assessment strategy. Research staff provided nephrologists a digital recorder to record nephrologist counselling discussions with LDs, rather than observing discussions in person. We adapted the observer checklist to be tailored to the study aims for fidelity monitoring purposes. Additional survey measures are being collected at all time points (eg, Generalised Anxiety Disorder 7-Item), and current measures are being collected at additional time points for additional situations for both arms. For example, we added Preparedness to Donate to all time points, the Preparation for Decision Making Scale is no longer asked at T1, but asked at T2, T3 and T4, and The Shared Decision-Making Questionnaire is being asked at T2 and T4 in addition to T3.</p>
            </sec>
            <sec sec-type="discussion" id="s4">
              <title>Discussion</title>
              <p>The results of this study will serve as a model for implementing genetic testing and counselling that improves the informed consent of living kidney donor candidates of African ancestry who are most at risk of having two <italic toggle="yes">APOL1</italic> risk variants. Because <italic toggle="yes">APOL1</italic> risk variants increase LD candidates’ risks of kidney failure post-donation, clinical practice guidelines recommend engaging in counselling, and many ethicists have argued that it is unethical to not inform donor candidates about their risks. Thus, it is essential that LD candidates of African ancestry receive culturally and ethically sound counselling to ensure that they make informed treatment decisions about donating. Ensuring that transplant counselling practices are culturally and ethically sound is especially important because transplant programmes currently vary on their use of counselling and SDM for LD candidates who underwent <italic toggle="yes">APOL1</italic> genetic testing.</p>
              <p>The model of integration of genetic testing and counselling in this study will be available for dissemination to other transplant programmes in the USA to improve informed decision-making for LD candidates and, thus, foster greater safety in the donation process. Specifically, this will demonstrate an effective strategy for how to scale up genetic counselling services through the use of chatbots to deliver foundational information and training nephrologists to deliver components of genetic counselling and SDM. Furthermore, this model will be important for demonstrating how to integrate genetic test results into the EHR to enhance streamlined clinical decision support for physicians.</p>
            </sec>
            <sec sec-type="supplementary-material">
              <title>Supplementary Material</title>
              <supplementary-material content-type="local-data" id="d64e454">
                <caption>
                  <title>Reviewer comments</title>
                </caption>
                <media xlink:href="bmjopen-2022-067657.reviewer_comments.pdf"/>
              </supplementary-material>
              <supplementary-material content-type="local-data" id="d64e455">
                <caption>
                  <title>Author's
manuscript</title>
                </caption>
                <media xlink:href="bmjopen-2022-067657.draft_revisions.pdf"/>
              </supplementary-material>
            </sec>
          </body>
          <back>
            <ack>
              <p>The authors wish to thank our collaborators from the Community Advisory Board in Chicago; our dedicated research teams at Northwestern University and Georgetown University; and the members of our scientific advisory board (Richard Formica, MD, Marie Chisholm-Burns, PharmD, MPH, MBA, FCCP, FASHP, FAST, Amy McGuire, JD, PhD, and Jesse Schold, PhD) and scientific consultants on this project (Mona Doshi, MD, Charmaine Royal, PhD, Richard R. Sharp, PhD) for providing sage guidance. Support for the formation of the CAB for this study was provided the NU Alliance for Research in Chicagoland Communities Partnership Development Seed Award.</p>
            </ack>
            <fn-group>
              <fn fn-type="other">
                <p><bold>Twitter:</bold> @ElisaJGordon</p>
              </fn>
              <fn fn-type="other">
                <p><bold>Contributors:</bold> EJG conceived of the study. EJG, JDS, CW, DD, AS and SD designed the study. EJG, JDS, AA, MC, AG, SD, JG-S, LNM and SD refined the design of intervention implementation. EJG, AA, AS, JF, CW, DD, MC, AG and JG-S contributed to Gia chatbot intervention development. EJG, AA, AS, JF, CY, MC, AG and JG-S contributed to Nephrologist APOL1 Counseling Training Program intervention development. EJG, AA and LVR contributed to Epic integration preparation. JDS and EJG collaborated in drafting the manuscript. All authors read, edited, and approved the final version of the manuscript to be published, and agree to be accountable for all aspects of the work.</p>
              </fn>
              <fn fn-type="other">
                <p><bold>Funding:</bold> This study is supported by grant 1R01DK128207-01 from the National Institute of Diabetes and Digestive and Kidney Diseases of the National Institutes of Health, awarded to Elisa J. Gordon. Additional support was provided by a grant from The Northwestern Medicine Dixon Translational Research Innovation Award awarded to Elisa J. Gordon, and the Alliance for Research in Chicagoland Communities/Northwestern University Clinical &amp; Translational Sciences Institute Community-Engaged Research Partnership Development Seed Grant awarded to Elisa J. Gordon and Jacqueline Burgess-Bishop. The opinions expressed herein are the views of the authors and do not necessarily reflect the official policy or position of the National Institute of Diabetes and Digestive and Kidney Diseases or any other part of the US Department of Health and Human Services.</p>
              </fn>
              <fn fn-type="COI-statement">
                <p><bold>Competing interests:</bold> None declared.</p>
              </fn>
              <fn fn-type="other">
                <p><bold>Patient and public involvement:</bold> Patients and/or the public were involved in the design, or conduct, or reporting, or dissemination plans of this research. Refer to the Methods section for further details.</p>
              </fn>
              <fn fn-type="other">
                <p><bold>Provenance and peer review:</bold> Not commissioned; externally peer reviewed.</p>
              </fn>
              <fn fn-type="other">
                <p><bold>Supplemental material:</bold> This content has been supplied by the author(s). It has not been vetted by BMJ Publishing Group Limited (BMJ) and may not have been peer-reviewed. Any opinions or recommendations discussed are solely those of the author(s) and are not endorsed by BMJ. BMJ disclaims all liability and responsibility arising from any reliance placed on the content. Where the content includes any translated material, BMJ does not warrant the accuracy and reliability of the translations (including but not limited to local regulations, clinical guidelines, terminology, drug names and drug dosages), and is not responsible for any error and/or omissions arising from translation and adaptation or otherwise.</p>
              </fn>
            </fn-group>
            <sec sec-type="ethics-statement">
              <title>Ethics statements</title>
              <sec>
                <title>Patient consent for publication</title>
                <p content-type="ethics-consent-to-publish">Not applicable.</p>
              </sec>
            </sec>
            <ref-list>
              <title>References</title>
              <ref id="R1">
                <label>1</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Cohen</surname><given-names>DM</given-names></string-name>, <string-name><surname>Mittalhenkle</surname><given-names>A</given-names></string-name>, <string-name><surname>Scott</surname><given-names>DL</given-names></string-name>, <etal>et al</etal></person-group>. <article-title>African American living-kidney donors should be screened for Apol1 risk alleles</article-title>. <source>Transplantation</source><year>2011</year>;<volume>92</volume>:<fpage>722</fpage>–<lpage>5</lpage>. <pub-id pub-id-type="doi">10.1097/TP.0b013e31822eec39</pub-id>
<pub-id pub-id-type="pmid">21878839</pub-id></mixed-citation>
              </ref>
              <ref id="R2">
                <label>2</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Matas</surname><given-names>AJ</given-names></string-name>, <string-name><surname>Bartlett</surname><given-names>ST</given-names></string-name>, <string-name><surname>Leichtman</surname><given-names>AB</given-names></string-name>, <etal>et al</etal></person-group>. <article-title>Morbidity and mortality after living kidney donation, 1999-2001: Survey of United States transplant centers</article-title>. <source>Am J Transplant</source><year>2003</year>;<volume>3</volume>:<fpage>830</fpage>–<lpage>4</lpage>. <pub-id pub-id-type="doi">10.1046/j.1038-5282.2001.00400.x-i1</pub-id>
<pub-id pub-id-type="pmid">12814474</pub-id></mixed-citation>
              </ref>
              <ref id="R3">
                <label>3</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Chkhotua</surname><given-names>AB</given-names></string-name>, <string-name><surname>Klein</surname><given-names>T</given-names></string-name>, <string-name><surname>Shabtai</surname><given-names>E</given-names></string-name>, <etal>et al</etal></person-group>. <article-title>Kidney transplantation from living-unrelated donors: Comparison of outcome with living-related and cadaveric transplants under current immunosuppressive protocols</article-title>. <source>Urology</source><year>2003</year>;<volume>62</volume>:<fpage>1002</fpage>–<lpage>6</lpage>. <pub-id pub-id-type="doi">10.1016/s0090-4295(03)00760-x</pub-id>
<pub-id pub-id-type="pmid">14665344</pub-id></mixed-citation>
              </ref>
              <ref id="R4">
                <label>4</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Gjertson</surname><given-names>DW</given-names></string-name>, <string-name><surname>Cecka</surname><given-names>JM</given-names></string-name></person-group>. <article-title>Living unrelated donor kidney transplantation</article-title>. <source>Kidney Int</source><year>2000</year>;<volume>58</volume>:<fpage>491</fpage>–<lpage>9</lpage>. <pub-id pub-id-type="doi">10.1046/j.1523-1755.2000.00195.x</pub-id>
<pub-id pub-id-type="pmid">10916072</pub-id></mixed-citation>
              </ref>
              <ref id="R5">
                <label>5</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Reese</surname><given-names>PP</given-names></string-name>, <string-name><surname>Shults</surname><given-names>J</given-names></string-name>, <string-name><surname>Bloom</surname><given-names>RD</given-names></string-name>, <etal>et al</etal></person-group>. <article-title>Functional status, time to transplantation, and survival benefit of kidney transplantation among wait-listed candidates</article-title>. <source>Am J Kidney Dis</source><year>2015</year>;<volume>66</volume>:<fpage>837</fpage>–<lpage>45</lpage>. <pub-id pub-id-type="doi">10.1053/j.ajkd.2015.05.015</pub-id>
<pub-id pub-id-type="pmid">26162652</pub-id></mixed-citation>
              </ref>
              <ref id="R6">
                <label>6</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>von der Lippe</surname><given-names>N</given-names></string-name>, <string-name><surname>Waldum</surname><given-names>B</given-names></string-name>, <string-name><surname>Brekke</surname><given-names>FB</given-names></string-name>, <etal>et al</etal></person-group>. <article-title>From dialysis to transplantation: A 5-year longitudinal study on self-reported quality of life</article-title>. <source>BMC Nephrology</source><year>2014</year>;<volume>15</volume>:<elocation-id>191</elocation-id>. <pub-id pub-id-type="doi">10.1186/1471-2369-15-191</pub-id><pub-id pub-id-type="pmid">25465066</pub-id></mixed-citation>
              </ref>
              <ref id="R7">
                <label>7</label>
                <mixed-citation publication-type="book"><person-group person-group-type="author"><collab>Organ Procurement Transplant Network</collab></person-group>. <source>Transplants by donor type. U.S. transplants performed: January 1, 1988 - October 31, 2019, kidney. Based on OPTN data as of May 12, 2020</source>. <year>2020</year>. <comment>Available</comment>: <uri xlink:href="http://optn.transplant.hrsa.gov/converge/latestData/rptData.asp">http://optn.transplant.hrsa.gov/converge/latestData/rptData.asp</uri> [accessed <comment>13 2020</comment>].</mixed-citation>
              </ref>
              <ref id="R8">
                <label>8</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Purnell</surname><given-names>TS</given-names></string-name>, <string-name><surname>Xu</surname><given-names>P</given-names></string-name>, <string-name><surname>Leca</surname><given-names>N</given-names></string-name>, <etal>et al</etal></person-group>. <article-title>Racial differences in determinants of live donor kidney transplantation in the United States</article-title>. <source>Am J Transplant</source><year>2013</year>;<volume>13</volume>:<fpage>1557</fpage>–<lpage>65</lpage>. <pub-id pub-id-type="doi">10.1111/ajt.12258</pub-id>
<pub-id pub-id-type="pmid">23669021</pub-id></mixed-citation>
              </ref>
              <ref id="R9">
                <label>9</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Muzaale</surname><given-names>AD</given-names></string-name>, <string-name><surname>Massie</surname><given-names>AB</given-names></string-name>, <string-name><surname>Wang</surname><given-names>M-C</given-names></string-name>, <etal>et al</etal></person-group>. <article-title>Risk of end-stage renal disease following live kidney donation</article-title>. <source>JAMA</source><year>2014</year>;<volume>311</volume>:<fpage>579</fpage>. <pub-id pub-id-type="doi">10.1001/jama.2013.285141</pub-id><pub-id pub-id-type="pmid">24519297</pub-id></mixed-citation>
              </ref>
              <ref id="R10">
                <label>10</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Grams</surname><given-names>ME</given-names></string-name>, <string-name><surname>Rebholz</surname><given-names>CM</given-names></string-name>, <string-name><surname>Chen</surname><given-names>Y</given-names></string-name>, <etal>et al</etal></person-group>. <article-title>Race, APOL1 risk, and eGFR decline in the general population</article-title>. <source>JASN</source><year>2016</year>;<volume>27</volume>:<fpage>2842</fpage>–<lpage>50</lpage>. <pub-id pub-id-type="doi">10.1681/ASN.2015070763</pub-id>
<pub-id pub-id-type="pmid">26966015</pub-id></mixed-citation>
              </ref>
              <ref id="R11">
                <label>11</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Tan</surname><given-names>JC</given-names></string-name>, <string-name><surname>Gordon</surname><given-names>EJ</given-names></string-name>, <string-name><surname>Dew</surname><given-names>MA</given-names></string-name>, <etal>et al</etal></person-group>. <article-title>Living donor kidney transplantation: Facilitating education about live kidney donation-recommendations from a consensus conference</article-title>. <source>CJASN</source><year>2015</year>;<volume>10</volume>:<fpage>1670</fpage>–<lpage>7</lpage>. <pub-id pub-id-type="doi">10.2215/CJN.01030115</pub-id>
<pub-id pub-id-type="pmid">25908792</pub-id></mixed-citation>
              </ref>
              <ref id="R12">
                <label>12</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Kasiske</surname><given-names>BL</given-names></string-name></person-group>. <article-title>Outcomes after living kidney donation: What we still need to know and why</article-title>. <source>Am J Kidney Dis</source><year>2014</year>;<volume>64</volume>:<fpage>335</fpage>–<lpage>7</lpage>. <pub-id pub-id-type="doi">10.1053/j.ajkd.2014.04.013</pub-id>
<pub-id pub-id-type="pmid">24797521</pub-id></mixed-citation>
              </ref>
              <ref id="R13">
                <label>13</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Gaston</surname><given-names>RS</given-names></string-name>, <string-name><surname>Kumar</surname><given-names>V</given-names></string-name>, <string-name><surname>Matas</surname><given-names>AJ</given-names></string-name></person-group>. <article-title>Reassessing medical risk in living kidney donors</article-title>. <source>J Am Soc Nephrol</source><year>2015</year>;<volume>26</volume>:<fpage>1017</fpage>–<lpage>9</lpage>. <pub-id pub-id-type="doi">10.1681/ASN.2014030227</pub-id>
<pub-id pub-id-type="pmid">25255922</pub-id></mixed-citation>
              </ref>
              <ref id="R14">
                <label>14</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Purnell</surname><given-names>TS</given-names></string-name>, <string-name><surname>Powe</surname><given-names>NR</given-names></string-name>, <string-name><surname>Troll</surname><given-names>MU</given-names></string-name>, <etal>et al</etal></person-group>. <article-title>Measuring and explaining racial and ethnic differences in willingness to donate live kidneys in the United States</article-title>. <source>Clin Transplant</source><year>2013</year>;<volume>27</volume>:<fpage>673</fpage>–<lpage>83</lpage>. <pub-id pub-id-type="doi">10.1111/ctr.12196</pub-id>
<pub-id pub-id-type="pmid">23902226</pub-id></mixed-citation>
              </ref>
              <ref id="R15">
                <label>15</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Tarver-Carr</surname><given-names>ME</given-names></string-name>, <string-name><surname>Powe</surname><given-names>NR</given-names></string-name>, <string-name><surname>Eberhardt</surname><given-names>MS</given-names></string-name>, <etal>et al</etal></person-group>. <article-title>Excess risk of chronic kidney disease among African-American versus white subjects in the United States: A population-based study of potential explanatory factors</article-title>. <source>JASN</source><year>2002</year>;<volume>13</volume>:<fpage>2363</fpage>–<lpage>70</lpage>. <pub-id pub-id-type="doi">10.1097/01.asn.0000026493.18542.6a</pub-id>
<pub-id pub-id-type="pmid">12191981</pub-id></mixed-citation>
              </ref>
              <ref id="R16">
                <label>16</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Genovese</surname><given-names>G</given-names></string-name>, <string-name><surname>Friedman</surname><given-names>DJ</given-names></string-name>, <string-name><surname>Ross</surname><given-names>MD</given-names></string-name>, <etal>et al</etal></person-group>. <article-title>Association of trypanolytic ApoL1 variants with kidney disease in African Americans</article-title>. <source>Science</source><year>2010</year>;<volume>329</volume>:<fpage>841</fpage>–<lpage>5</lpage>. <pub-id pub-id-type="doi">10.1126/science.1193032</pub-id>
<pub-id pub-id-type="pmid">20647424</pub-id></mixed-citation>
              </ref>
              <ref id="R17">
                <label>17</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Tzur</surname><given-names>S</given-names></string-name>, <string-name><surname>Rosset</surname><given-names>S</given-names></string-name>, <string-name><surname>Shemer</surname><given-names>R</given-names></string-name>, <etal>et al</etal></person-group>. <article-title>Missense mutations in the APOL1 gene are highly associated with end stage kidney disease risk previously attributed to the MYH9 gene</article-title>. <source>Hum Genet</source><year>2010</year>;<volume>128</volume>:<fpage>345</fpage>–<lpage>50</lpage>. <pub-id pub-id-type="doi">10.1007/s00439-010-0861-0</pub-id>
<pub-id pub-id-type="pmid">20635188</pub-id></mixed-citation>
              </ref>
              <ref id="R18">
                <label>18</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Parsa</surname><given-names>A</given-names></string-name>, <string-name><surname>Kao</surname><given-names>WHL</given-names></string-name>, <string-name><surname>Xie</surname><given-names>D</given-names></string-name>, <etal>et al</etal></person-group>. <article-title>APOL1 risk variants, race, and progression of chronic kidney disease</article-title>. <source>N Engl J Med</source><year>2013</year>;<volume>369</volume>:<fpage>2183</fpage>–<lpage>96</lpage>. <pub-id pub-id-type="doi">10.1056/NEJMoa1310345</pub-id>
<pub-id pub-id-type="pmid">24206458</pub-id></mixed-citation>
              </ref>
              <ref id="R19">
                <label>19</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Friedman</surname><given-names>DJ</given-names></string-name>, <string-name><surname>Kozlitina</surname><given-names>J</given-names></string-name>, <string-name><surname>Genovese</surname><given-names>G</given-names></string-name>, <etal>et al</etal></person-group>. <article-title>Population-based risk assessment of APOL1 on renal disease</article-title>. <source>J Am Soc Nephrol</source><year>2011</year>;<volume>22</volume>:<fpage>2098</fpage>–<lpage>105</lpage>. <pub-id pub-id-type="doi">10.1681/ASN.2011050519</pub-id>
<pub-id pub-id-type="pmid">21997396</pub-id></mixed-citation>
              </ref>
              <ref id="R20">
                <label>20</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Quaggin</surname><given-names>SE</given-names></string-name>, <string-name><surname>George</surname><given-names>AL</given-names></string-name></person-group>. <article-title>Apolipoprotein L1 and the genetic basis for racial disparity in chronic kidney disease</article-title>. <source>JASN</source><year>2011</year>;<volume>22</volume>:<fpage>1955</fpage>–<lpage>8</lpage>. <pub-id pub-id-type="doi">10.1681/ASN.2011090932</pub-id>
<pub-id pub-id-type="pmid">21997393</pub-id></mixed-citation>
              </ref>
              <ref id="R21">
                <label>21</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Reeves-Daniel</surname><given-names>AM</given-names></string-name>, <string-name><surname>DePalma</surname><given-names>JA</given-names></string-name>, <string-name><surname>Bleyer</surname><given-names>AJ</given-names></string-name>, <etal>et al</etal></person-group>. <article-title>The Apol1 gene and allograft survival after kidney transplantation</article-title>. <source>Am J Transplant</source><year>2011</year>;<volume>11</volume>:<fpage>1025</fpage>–<lpage>30</lpage>. <pub-id pub-id-type="doi">10.1111/j.1600-6143.2011.03513.x</pub-id>
<pub-id pub-id-type="pmid">21486385</pub-id></mixed-citation>
              </ref>
              <ref id="R22">
                <label>22</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Freedman</surname><given-names>BI</given-names></string-name>, <string-name><surname>Julian</surname><given-names>BA</given-names></string-name>, <string-name><surname>Pastan</surname><given-names>SO</given-names></string-name>, <etal>et al</etal></person-group>. <article-title>Apolipoprotein L1 gene variants in deceased organ donors are associated with renal allograft failure</article-title>. <source>Am J Transplant</source><year>2015</year>;<volume>15</volume>:<fpage>1615</fpage>–<lpage>22</lpage>. <pub-id pub-id-type="doi">10.1111/ajt.13223</pub-id>
<pub-id pub-id-type="pmid">25809272</pub-id></mixed-citation>
              </ref>
              <ref id="R23">
                <label>23</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Locke</surname><given-names>JE</given-names></string-name>, <string-name><surname>Sawinski</surname><given-names>D</given-names></string-name>, <string-name><surname>Reed</surname><given-names>RD</given-names></string-name>, <etal>et al</etal></person-group>. <article-title>Apolipoprotein L1 and chronic kidney disease risk in young potential living kidney donors</article-title>. <source>Ann Surg</source><year>2018</year>;<volume>267</volume>:<fpage>1161</fpage>–<lpage>8</lpage>. <pub-id pub-id-type="doi">10.1097/SLA.0000000000002174</pub-id>
<pub-id pub-id-type="pmid">28187045</pub-id></mixed-citation>
              </ref>
              <ref id="R24">
                <label>24</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Lentine</surname><given-names>KL</given-names></string-name>, <string-name><surname>Kasiske</surname><given-names>BL</given-names></string-name>, <string-name><surname>Levey</surname><given-names>AS</given-names></string-name>, <etal>et al</etal></person-group>. <article-title>KDIGO clinical practice guideline on the evaluation and care of living kidney donors</article-title>. <source>Transplantation</source><year>2017</year>;<volume>101</volume>:<fpage>S7</fpage>–<lpage>S105</lpage>. <pub-id pub-id-type="doi">10.1097/TP.0000000000001769</pub-id>
</mixed-citation>
              </ref>
              <ref id="R25">
                <label>25</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Newell</surname><given-names>KA</given-names></string-name>, <string-name><surname>Formica</surname><given-names>RN</given-names></string-name>, <string-name><surname>Gill</surname><given-names>JS</given-names></string-name>, <etal>et al</etal></person-group>. <article-title>Integrating Apol1 gene variants into renal transplantation: Considerations arising from the American Society of Transplantation expert conference</article-title>. <source>Am J Transplant</source><year>2017</year>;<volume>17</volume>:<fpage>901</fpage>–<lpage>11</lpage>. <pub-id pub-id-type="doi">10.1111/ajt.14173</pub-id>
<pub-id pub-id-type="pmid">27997071</pub-id></mixed-citation>
              </ref>
              <ref id="R26">
                <label>26</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Riella</surname><given-names>LV</given-names></string-name>, <string-name><surname>Sheridan</surname><given-names>AM</given-names></string-name></person-group>. <article-title>Testing for high-risk APOL1 alleles in potential living kidney donors</article-title>. <source>Am J Kidney Dis</source><year>2015</year>;<volume>66</volume>:<fpage>396</fpage>–<lpage>401</lpage>. <pub-id pub-id-type="doi">10.1053/j.ajkd.2015.04.046</pub-id>
<pub-id pub-id-type="pmid">26049628</pub-id></mixed-citation>
              </ref>
              <ref id="R27">
                <label>27</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Ojo</surname><given-names>A</given-names></string-name>, <string-name><surname>Knoll</surname><given-names>GA</given-names></string-name></person-group>. <article-title>Apol1 genotyping of African American deceased organ donors: Not just yet</article-title>. <source>Am J Transplant</source><year>2015</year>;<volume>15</volume>:<fpage>1457</fpage>–<lpage>8</lpage>. <pub-id pub-id-type="doi">10.1111/ajt.13230</pub-id>
<pub-id pub-id-type="pmid">25809950</pub-id></mixed-citation>
              </ref>
              <ref id="R28">
                <label>28</label>
                <mixed-citation publication-type="webpage"><person-group person-group-type="author"><collab>U.S. National Library of Medicine, ClinicalTrials.gov</collab></person-group>. <article-title>APOL1 long-term kidney transplantation outcomes network (Apollo)</article-title>, <year>2018</year>. Available: <uri xlink:href="https://clinicaltrials.gov/ct2/show/NCT03615235">https://clinicaltrials.gov/ct2/show/NCT03615235</uri></mixed-citation>
              </ref>
              <ref id="R29">
                <label>29</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Freedman</surname><given-names>BI</given-names></string-name>, <string-name><surname>Julian</surname><given-names>BA</given-names></string-name></person-group>. <article-title>Should kidney donors be genotyped for APOL1 risk alleles?</article-title><source>Kidney Int</source><year>2015</year>;<volume>87</volume>:<fpage>671</fpage>–<lpage>3</lpage>. <pub-id pub-id-type="doi">10.1038/ki.2015.16</pub-id>
<pub-id pub-id-type="pmid">25826538</pub-id></mixed-citation>
              </ref>
              <ref id="R30">
                <label>30</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Mohan</surname><given-names>S</given-names></string-name>, <string-name><surname>Iltis</surname><given-names>AS</given-names></string-name>, <string-name><surname>Sawinski</surname><given-names>D</given-names></string-name>, <etal>et al</etal></person-group>. <article-title>Apol1 genetic testing in living kidney transplant donors</article-title>. <source>Am J Kidney Dis</source><year>2019</year>;<volume>74</volume>:<fpage>538</fpage>–<lpage>43</lpage>. <pub-id pub-id-type="doi">10.1053/j.ajkd.2019.02.007</pub-id>
<pub-id pub-id-type="pmid">30982552</pub-id></mixed-citation>
              </ref>
              <ref id="R31">
                <label>31</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><collab>Ethics Committee of the Transplantation Society</collab></person-group>. <article-title>The consensus statement of the Amsterdam forum on the care of the live kidney donor</article-title>. <source>Transplantation</source><year>2004</year>;<volume>78</volume>:<fpage>491</fpage>–<lpage>2</lpage>. <pub-id pub-id-type="doi">10.1097/01.tp.0000136654.85459.1e</pub-id>
<pub-id pub-id-type="pmid">15446304</pub-id></mixed-citation>
              </ref>
              <ref id="R32">
                <label>32</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Gordon</surname><given-names>EJ</given-names></string-name></person-group>. <article-title>Informed consent for living donation: A review of key empirical studies, ethical challenges and future research</article-title>. <source>Am J Transplant</source><year>2012</year>;<volume>12</volume>:<fpage>2273</fpage>–<lpage>80</lpage>. <pub-id pub-id-type="doi">10.1111/j.1600-6143.2012.04102.x</pub-id>
<pub-id pub-id-type="pmid">22594620</pub-id></mixed-citation>
              </ref>
              <ref id="R33">
                <label>33</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Abecassis</surname><given-names>M</given-names></string-name>, <string-name><surname>Adams</surname><given-names>M</given-names></string-name>, <string-name><surname>Adams</surname><given-names>P</given-names></string-name>, <etal>et al</etal></person-group>. <article-title>Consensus statement on the live organ donor</article-title>. <source>JAMA</source><year>2000</year>;<volume>284</volume>:<fpage>2919</fpage>–<lpage>26</lpage>. <pub-id pub-id-type="doi">10.1001/jama.284.22.2919</pub-id>
<pub-id pub-id-type="pmid">11187711</pub-id></mixed-citation>
              </ref>
              <ref id="R34">
                <label>34</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Purnell</surname><given-names>TS</given-names></string-name>, <string-name><surname>Luo</surname><given-names>X</given-names></string-name>, <string-name><surname>Cooper</surname><given-names>LA</given-names></string-name>, <etal>et al</etal></person-group>. <article-title>Association of race and Ethnicity with live donor kidney transplantation in the United States from 1995 to 2014</article-title>. <source>JAMA</source><year>2018</year>;<volume>319</volume>:<fpage>49</fpage>–<lpage>61</lpage>. <pub-id pub-id-type="doi">10.1001/jama.2017.19152</pub-id>
<pub-id pub-id-type="pmid">29297077</pub-id></mixed-citation>
              </ref>
              <ref id="R35">
                <label>35</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Gordon</surname><given-names>EJ</given-names></string-name>, <string-name><surname>Butt</surname><given-names>Z</given-names></string-name>, <string-name><surname>Jensen</surname><given-names>SE</given-names></string-name>, <etal>et al</etal></person-group>. <article-title>Opportunities for shared decision making in kidney transplantation</article-title>. <source>Am J Transplant</source><year>2013</year>;<volume>13</volume>:<fpage>1149</fpage>–<lpage>58</lpage>. <pub-id pub-id-type="doi">10.1111/ajt.12195</pub-id>
<pub-id pub-id-type="pmid">23489435</pub-id></mixed-citation>
              </ref>
              <ref id="R36">
                <label>36</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Gordon</surname><given-names>EJ</given-names></string-name>, <string-name><surname>Wicklund</surname><given-names>C</given-names></string-name>, <string-name><surname>Lee</surname><given-names>J</given-names></string-name>, <etal>et al</etal></person-group>. <article-title>A national survey of transplant surgeons and nephrologists on implementing Apolipoprotein L1 (APOL1) genetic testing into clinical practice</article-title>. <source>Prog Transpl</source><year>2019</year>;<volume>29</volume>:<fpage>26</fpage>–<lpage>35</lpage>. <pub-id pub-id-type="doi">10.1177/1526924818817048</pub-id>
</mixed-citation>
              </ref>
              <ref id="R37">
                <label>37</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>McIntosh</surname><given-names>T</given-names></string-name>, <string-name><surname>Mohan</surname><given-names>S</given-names></string-name>, <string-name><surname>Sawinski</surname><given-names>D</given-names></string-name>, <etal>et al</etal></person-group>. <article-title>Variation of ApoL1 testing practices for living kidney donors</article-title>. <source>Prog Transplant</source><year>2020</year>;<volume>30</volume>:<fpage>22</fpage>–<lpage>8</lpage>. <pub-id pub-id-type="doi">10.1177/1526924819892917</pub-id>
<pub-id pub-id-type="pmid">31838940</pub-id></mixed-citation>
              </ref>
              <ref id="R38">
                <label>38</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Nestor</surname><given-names>JG</given-names></string-name>, <string-name><surname>Li</surname><given-names>AJ</given-names></string-name>, <string-name><surname>King</surname><given-names>KL</given-names></string-name>, <etal>et al</etal></person-group>. <article-title>Impact of education on APOL1 testing attitudes among prospective living kidney donors</article-title>. <source>Clin Transplant</source><year>2022</year>;<volume>36</volume>:<elocation-id>e14516</elocation-id>. <pub-id pub-id-type="doi">10.1111/ctr.14516</pub-id><pub-id pub-id-type="pmid">34661305</pub-id></mixed-citation>
              </ref>
              <ref id="R39">
                <label>39</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Doshi</surname><given-names>MD</given-names></string-name>, <string-name><surname>Gordon</surname><given-names>EJ</given-names></string-name>, <string-name><surname>Freedman</surname><given-names>BI</given-names></string-name>, <etal>et al</etal></person-group>. <article-title>Integrating Apol1 kidney-risk variant testing in live kidney donor evaluation: An expert panel opinion</article-title>. <source>Transplantation</source><year>2021</year>;<volume>105</volume>:<fpage>2132</fpage>–<lpage>4</lpage>. <pub-id pub-id-type="doi">10.1097/TP.0000000000003641</pub-id>
<pub-id pub-id-type="pmid">33534524</pub-id></mixed-citation>
              </ref>
              <ref id="R40">
                <label>40</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Resta</surname><given-names>R</given-names></string-name>, <string-name><surname>Biesecker</surname><given-names>BB</given-names></string-name>, <etal>et al</etal></person-group>. <article-title>A new definition of genetic counseling: National Society of Genetic Counselors’ Task Force Report</article-title>. <source>J Genet Couns</source><year>2006</year>;<volume>15</volume>:<fpage>77</fpage>–<lpage>83</lpage>. <pub-id pub-id-type="doi">10.1007/s10897-005-9014-3</pub-id>
<pub-id pub-id-type="pmid">16761103</pub-id></mixed-citation>
              </ref>
              <ref id="R41">
                <label>41</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Madlensky</surname><given-names>L</given-names></string-name>, <string-name><surname>Trepanier</surname><given-names>AM</given-names></string-name>, <string-name><surname>Cragun</surname><given-names>D</given-names></string-name>, <etal>et al</etal></person-group>. <article-title>A rapid systematic review of outcomes studies in genetic counseling</article-title>. <source>J Genet Couns</source><year>2017</year>;<volume>26</volume>:<fpage>361</fpage>–<lpage>78</lpage>. <pub-id pub-id-type="doi">10.1007/s10897-017-0067-x</pub-id>
<pub-id pub-id-type="pmid">28168332</pub-id></mixed-citation>
              </ref>
              <ref id="R42">
                <label>42</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Kranenburg</surname><given-names>LW</given-names></string-name>, <string-name><surname>Zuidema</surname><given-names>WC</given-names></string-name>, <string-name><surname>Weimar</surname><given-names>W</given-names></string-name>, <etal>et al</etal></person-group>. <article-title>Psychological barriers for living kidney donation: How to inform the potential donors?</article-title><source>Transplantation</source><year>2007</year>;<volume>84</volume>:<fpage>965</fpage>–<lpage>71</lpage>. <pub-id pub-id-type="doi">10.1097/01.tp.0000284981.83557.dc</pub-id>
<pub-id pub-id-type="pmid">17989601</pub-id></mixed-citation>
              </ref>
              <ref id="R43">
                <label>43</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Liu</surname><given-names>K-L</given-names></string-name>, <string-name><surname>Wang</surname><given-names>H-H</given-names></string-name>, <string-name><surname>Hsieh</surname><given-names>C-Y</given-names></string-name>, <etal>et al</etal></person-group>. <article-title>Kidney donation withdrawal and related factors among the potential donors of living kidney transplant</article-title>. <source>Transplant Proc</source><year>2020</year>;<volume>52</volume>:<fpage>73</fpage>–<lpage>7</lpage>. <pub-id pub-id-type="doi">10.1016/j.transproceed.2019.11.018</pub-id>
<pub-id pub-id-type="pmid">31901327</pub-id></mixed-citation>
              </ref>
              <ref id="R44">
                <label>44</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Yi</surname><given-names>M</given-names></string-name></person-group>. <article-title>Decision-Making process for living kidney donors</article-title>. <source>J Nurs Scholarsh</source><year>2003</year>;<volume>35</volume>:<fpage>61</fpage>–<lpage>6</lpage>. <pub-id pub-id-type="doi">10.1111/j.1547-5069.2003.00061.x</pub-id>
<pub-id pub-id-type="pmid">12701528</pub-id></mixed-citation>
              </ref>
              <ref id="R45">
                <label>45</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Burroughs</surname><given-names>TE</given-names></string-name>, <string-name><surname>Waterman</surname><given-names>AD</given-names></string-name>, <string-name><surname>Hong</surname><given-names>BA</given-names></string-name></person-group>. <article-title>One organ donation, three perspectives: Experiences of donors, recipients, and third parties with living kidney donation</article-title>. <source>Prog Transpl</source><year>2003</year>;<volume>13</volume>:<fpage>142</fpage>–<lpage>50</lpage>. <pub-id pub-id-type="doi">10.1177/152692480301300212</pub-id>
</mixed-citation>
              </ref>
              <ref id="R46">
                <label>46</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Sanner</surname><given-names>MA</given-names></string-name></person-group>. <article-title>The donation process of living kidney donors</article-title>. <source>Nephrology, Dialysis, Transplantation</source><year>2005</year>;<volume>20</volume>:<fpage>1707</fpage>–<lpage>13</lpage>.</mixed-citation>
              </ref>
              <ref id="R47">
                <label>47</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Gordon</surname><given-names>EJ</given-names></string-name>, <string-name><surname>Amόrtegui</surname><given-names>D</given-names></string-name>, <string-name><surname>Blancas</surname><given-names>I</given-names></string-name>, <etal>et al</etal></person-group>. <article-title>African American living donors’ attitudes about APOL1 genetic testing: A mixed methods study</article-title>. <source>Am J Kid Dis</source><year>2018</year>;<volume>72</volume>:<fpage>819</fpage>–<lpage>33</lpage>. <pub-id pub-id-type="doi">10.1053/j.ajkd.2018.07.017</pub-id>
<pub-id pub-id-type="pmid">30360961</pub-id></mixed-citation>
              </ref>
              <ref id="R48">
                <label>48</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Gordon</surname><given-names>EJ</given-names></string-name>, <string-name><surname>Amórtegui</surname><given-names>D</given-names></string-name>, <string-name><surname>Blancas</surname><given-names>I</given-names></string-name>, <etal>et al</etal></person-group>. <article-title>A focus group study on African American living donors' treatment preferences, sociocultural factors, and health beliefs about Apolipoprotein L1 genetic testing</article-title>. <source>Prog Transplantation</source><year>2019</year>;<volume>29</volume>:<fpage>239</fpage>–<lpage>47</lpage>. <pub-id pub-id-type="doi">10.1177/1526924819854485</pub-id>
</mixed-citation>
              </ref>
              <ref id="R49">
                <label>49</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Vorderstrasse</surname><given-names>A</given-names></string-name>, <string-name><surname>Katsanis</surname><given-names>SH</given-names></string-name>, <string-name><surname>Minear</surname><given-names>MA</given-names></string-name>, <etal>et al</etal></person-group>. <article-title>Perceptions of personalized medicine in an academic health system: Educational findings</article-title>. <source>J Contemp Med Educ</source><year>2015</year>;<volume>3</volume>:<fpage>14</fpage>–<lpage>19</lpage>. <pub-id pub-id-type="doi">10.5455/jcme.20150408050414</pub-id>
<pub-id pub-id-type="pmid">26236542</pub-id></mixed-citation>
              </ref>
              <ref id="R50">
                <label>50</label>
                <mixed-citation publication-type="book"><article-title>Institute of Medicine. Improving genetics education in graduate and continuing health professional education</article-title>. <publisher-loc>Washington, D.C.</publisher-loc>, <publisher-name>The National Academies Press</publisher-name><month>March</month><year>2015</year>. <pub-id pub-id-type="doi">10.17226/18992</pub-id></mixed-citation>
              </ref>
              <ref id="R51">
                <label>51</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Dougherty</surname><given-names>MJ</given-names></string-name>, <string-name><surname>Wicklund</surname><given-names>C</given-names></string-name>, <string-name><surname>Johansen Taber</surname><given-names>KA</given-names></string-name></person-group>. <article-title>Challenges and opportunities for genomics education: Insights from an Institute of Medicine roundtable activity</article-title>. <source>JCEHP</source><year>2016</year>;<volume>36</volume>:<fpage>82</fpage>–<lpage>5</lpage>. <pub-id pub-id-type="doi">10.1097/CEH.0000000000000019</pub-id>
<pub-id pub-id-type="pmid">26954250</pub-id></mixed-citation>
              </ref>
              <ref id="R52">
                <label>52</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Korf</surname><given-names>BR</given-names></string-name>, <string-name><surname>Berry</surname><given-names>AB</given-names></string-name>, <string-name><surname>Limson</surname><given-names>M</given-names></string-name>, <etal>et al</etal></person-group>. <article-title>Framework for development of physician competencies in genomic medicine: Report of the competencies working group of the inter-society coordinating committee for physician education in genomics</article-title>. <source>Genet Med</source><year>2014</year>;<volume>16</volume>:<fpage>804</fpage>–<lpage>9</lpage>. <pub-id pub-id-type="doi">10.1038/gim.2014.35</pub-id>
<pub-id pub-id-type="pmid">24763287</pub-id></mixed-citation>
              </ref>
              <ref id="R53">
                <label>53</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Feero</surname><given-names>WG</given-names></string-name>, <string-name><surname>Manolio</surname><given-names>TA</given-names></string-name>, <string-name><surname>Khoury</surname><given-names>MJ</given-names></string-name></person-group>. <article-title>Translational research is a key to nongeneticist physicians' genomics education</article-title>. <source>Genet Med</source><year>2014</year>;<volume>16</volume>:<fpage>871</fpage>–<lpage>3</lpage>. <pub-id pub-id-type="doi">10.1038/gim.2014.67</pub-id>
<pub-id pub-id-type="pmid">24875299</pub-id></mixed-citation>
              </ref>
              <ref id="R54">
                <label>54</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Williams</surname><given-names>MS</given-names></string-name>, <string-name><surname>Taylor</surname><given-names>CO</given-names></string-name>, <string-name><surname>Walton</surname><given-names>NA</given-names></string-name>, <etal>et al</etal></person-group>. <article-title>Genomic information for clinicians in the electronic health record: Lessons learned from the clinical genome resource project and the electronic medical records and genomics network</article-title>. <source>Front Genet</source><year>2019</year>;<volume>10</volume>:<elocation-id>1059</elocation-id>. <pub-id pub-id-type="doi">10.3389/fgene.2019.01059</pub-id><pub-id pub-id-type="pmid">31737042</pub-id></mixed-citation>
              </ref>
              <ref id="R55">
                <label>55</label>
                <mixed-citation publication-type="book"><person-group person-group-type="author"><string-name><surname>Marks</surname><given-names>J</given-names></string-name></person-group>. <source>Is Science Racist</source>. <publisher-loc>Cambridge, UK</publisher-loc>: <publisher-name>Polity Press</publisher-name>, <year>2017</year>.</mixed-citation>
              </ref>
              <ref id="R56">
                <label>56</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Braveman</surname><given-names>PA</given-names></string-name>, <string-name><surname>Arkin</surname><given-names>E</given-names></string-name>, <string-name><surname>Proctor</surname><given-names>D</given-names></string-name>, <etal>et al</etal></person-group>. <article-title>Systemic and structural racism: Definitions, examples, health damages, and approaches to dismantling</article-title>. <source>Health Aff</source><year>2022</year>;<volume>41</volume>:<fpage>171</fpage>–<lpage>8</lpage>. <pub-id pub-id-type="doi">10.1377/hlthaff.2021.01394</pub-id>
</mixed-citation>
              </ref>
              <ref id="R57">
                <label>57</label>
                <mixed-citation publication-type="journal"><article-title>National Institute of Minority Health Disparities</article-title>. <source>National Institute on Minority Health and Health Disparities Research Framework</source><uri xlink:href="https://nimhd.nih.gov/researchFramework">https://nimhd.nih.gov/researchFramework</uri></mixed-citation>
              </ref>
              <ref id="R58">
                <label>58</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Purnell</surname><given-names>TS</given-names></string-name>, <string-name><surname>Simpson</surname><given-names>DC</given-names></string-name>, <string-name><surname>Callender</surname><given-names>CO</given-names></string-name>, <etal>et al</etal></person-group>. <article-title>Dismantling structural racism as a root cause of racial disparities in COVID-19 and transplantation</article-title>. <source>Am J Transplant</source><year>2021</year>;<volume>21</volume>:<fpage>2327</fpage>–<lpage>32</lpage>. <pub-id pub-id-type="doi">10.1111/ajt.16543</pub-id>
<pub-id pub-id-type="pmid">33599027</pub-id></mixed-citation>
              </ref>
              <ref id="R59">
                <label>59</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Mohottige</surname><given-names>D</given-names></string-name>, <string-name><surname>McElroy</surname><given-names>LM</given-names></string-name>, <string-name><surname>Boulware</surname><given-names>LE</given-names></string-name></person-group>. <article-title>A cascade of structural barriers contributing to racial kidney transplant inequities</article-title>. <source>Adv Chronic Kidney Dis</source><year>2021</year>;<volume>28</volume>:<fpage>517</fpage>–<lpage>27</lpage>. <pub-id pub-id-type="doi">10.1053/j.ackd.2021.10.009</pub-id>
<pub-id pub-id-type="pmid">35367020</pub-id></mixed-citation>
              </ref>
              <ref id="R60">
                <label>60</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Sussner</surname><given-names>KM</given-names></string-name>, <string-name><surname>Edwards</surname><given-names>TA</given-names></string-name>, <string-name><surname>Thompson</surname><given-names>HS</given-names></string-name>, <etal>et al</etal></person-group>. <article-title>Ethnic, racial and cultural identity and perceived benefits and barriers related to genetic testing for breast cancer among at-risk women of African descent in New York City</article-title>. <source>Public Health Genomics</source><year>2011</year>;<volume>14</volume>:<fpage>356</fpage>–<lpage>70</lpage>. <pub-id pub-id-type="doi">10.1159/000325263</pub-id>
<pub-id pub-id-type="pmid">21540561</pub-id></mixed-citation>
              </ref>
              <ref id="R61">
                <label>61</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Scott</surname><given-names>DM</given-names></string-name>, <string-name><surname>Thomas</surname><given-names>VG</given-names></string-name>, <string-name><surname>Otado</surname><given-names>J</given-names></string-name>, <etal>et al</etal></person-group>. <article-title>Attitudes and experiences regarding genetic research among persons of African descent</article-title>. <source>Journal of Community Genetics</source><year>2020</year>;<volume>11</volume>:<fpage>65</fpage>–<lpage>72</lpage>. <pub-id pub-id-type="doi">10.1007/s12687-019-00422-x</pub-id>
<pub-id pub-id-type="pmid">31062230</pub-id></mixed-citation>
              </ref>
              <ref id="R62">
                <label>62</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Umeukeje</surname><given-names>EM</given-names></string-name>, <string-name><surname>Young</surname><given-names>BA</given-names></string-name>, <string-name><surname>Fullerton</surname><given-names>SM</given-names></string-name>, <etal>et al</etal></person-group>. <article-title>You are just now telling us about this? African American perspectives of testing for genetic susceptibility to kidney disease</article-title>. <source>JASN</source><year>2019</year>;<volume>30</volume>:<fpage>526</fpage>–<lpage>30</lpage>. <pub-id pub-id-type="doi">10.1681/ASN.2018111091</pub-id>
<pub-id pub-id-type="pmid">30858224</pub-id></mixed-citation>
              </ref>
              <ref id="R63">
                <label>63</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Young</surname><given-names>BA</given-names></string-name>, <string-name><surname>Blacksher</surname><given-names>E</given-names></string-name>, <string-name><surname>Cavanaugh</surname><given-names>KL</given-names></string-name>, <etal>et al</etal></person-group>. <article-title>Apolipoprotein L1 testing in African Americans: Involving the community in policy discussions</article-title>. <source>Am J Nephrol</source><year>2019</year>;<volume>50</volume>:<fpage>303</fpage>–<lpage>11</lpage>. <pub-id pub-id-type="doi">10.1159/000502675</pub-id>
<pub-id pub-id-type="pmid">31480040</pub-id></mixed-citation>
              </ref>
              <ref id="R64">
                <label>64</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Arriola</surname><given-names>KRJ</given-names></string-name>, <string-name><surname>Powell</surname><given-names>CL</given-names></string-name>, <string-name><surname>Thompson</surname><given-names>NJ</given-names></string-name>, <etal>et al</etal></person-group>. <article-title>Living donor transplant education for African American patients with end-stage renal disease</article-title>. <source>Prog Transplantation</source><year>2014</year>;<volume>24</volume>:<fpage>362</fpage>–<lpage>70</lpage>. <pub-id pub-id-type="doi">10.7182/pit2014830</pub-id>
</mixed-citation>
              </ref>
              <ref id="R65">
                <label>65</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Rodrigue</surname><given-names>JR</given-names></string-name>, <string-name><surname>Paek</surname><given-names>MJ</given-names></string-name>, <string-name><surname>Egbuna</surname><given-names>O</given-names></string-name>, <etal>et al</etal></person-group>. <article-title>Making house calls increases living donor inquiries and evaluations for blacks on the kidney transplant waiting list</article-title>. <source>Transplantation</source><year>2014</year>;<volume>98</volume>:<fpage>979</fpage>–<lpage>86</lpage>. <pub-id pub-id-type="doi">10.1097/TP.0000000000000165</pub-id>
<pub-id pub-id-type="pmid">24825528</pub-id></mixed-citation>
              </ref>
              <ref id="R66">
                <label>66</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Gordon</surname><given-names>EJ</given-names></string-name>, <string-name><surname>Feinglass</surname><given-names>J</given-names></string-name>, <string-name><surname>Carney</surname><given-names>P</given-names></string-name>, <etal>et al</etal></person-group>. <article-title>A culturally targeted website for Hispanics/Latinos about living kidney donation and transplantation: A randomized controlled trial of increased knowledge</article-title>. <source>Transplantation</source><year>2016</year>;<volume>100</volume>:<fpage>1149</fpage>–<lpage>60</lpage>.<pub-id pub-id-type="pmid">26444846</pub-id></mixed-citation>
              </ref>
              <ref id="R67">
                <label>67</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Gordon</surname><given-names>EJ</given-names></string-name>, <string-name><surname>Lee</surname><given-names>J</given-names></string-name>, <string-name><surname>Kang</surname><given-names>RH</given-names></string-name>, <etal>et al</etal></person-group>. <article-title>A complex culturally targeted intervention to reduce Hispanic disparities in living kidney donor transplantation: An effectiveness-implementation hybrid study protocol</article-title>. <source>BMC Health Serv Res</source><year>2018</year>;<volume>18</volume>:<elocation-id>368</elocation-id>. <pub-id pub-id-type="doi">10.1186/s12913-018-3151-5</pub-id><pub-id pub-id-type="pmid">29769080</pub-id></mixed-citation>
              </ref>
              <ref id="R68">
                <label>68</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Aarons</surname><given-names>GA</given-names></string-name>, <string-name><surname>Sklar</surname><given-names>M</given-names></string-name>, <string-name><surname>Mustanski</surname><given-names>B</given-names></string-name>, <etal>et al</etal></person-group>. <article-title>"Scaling-out" evidence-based interventions to new populations or new health care delivery systems</article-title>. <source>Implement Sci</source><year>2017</year>;<volume>12</volume>:<fpage>111</fpage>. <pub-id pub-id-type="doi">10.1186/s13012-017-0640-6</pub-id><pub-id pub-id-type="pmid">28877746</pub-id></mixed-citation>
              </ref>
              <ref id="R69">
                <label>69</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Curran</surname><given-names>GM</given-names></string-name>, <string-name><surname>Bauer</surname><given-names>M</given-names></string-name>, <string-name><surname>Mittman</surname><given-names>B</given-names></string-name>, <etal>et al</etal></person-group>. <article-title>Effectiveness-implementation hybrid designs: Combining elements of clinical effectiveness and implementation research to enhance public health impact</article-title>. <source>Medical care</source><year>2012</year>;<volume>50</volume>:<fpage>217</fpage>–<lpage>26</lpage>. <pub-id pub-id-type="doi">10.1097/MLR.0b013e3182408812</pub-id>
<pub-id pub-id-type="pmid">22310560</pub-id></mixed-citation>
              </ref>
              <ref id="R70">
                <label>70</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Landes</surname><given-names>SJ</given-names></string-name>, <string-name><surname>McBain</surname><given-names>SA</given-names></string-name>, <string-name><surname>Curran</surname><given-names>GM</given-names></string-name></person-group>. <article-title>An introduction to effectiveness-implementation hybrid designs</article-title>. <source>Psychiatry Res</source><year>2019</year>;<volume>280</volume>:<elocation-id>112513</elocation-id>. <pub-id pub-id-type="doi">10.1016/j.psychres.2019.112513</pub-id><pub-id pub-id-type="pmid">31434011</pub-id></mixed-citation>
              </ref>
              <ref id="R71">
                <label>71</label>
                <mixed-citation publication-type="webpage"><person-group person-group-type="author"><collab>U.S. Census Bureau</collab></person-group>. <article-title>2013-2017 American community survey 5-year estimates</article-title>. <year>2017</year>. <comment>Available</comment>: <uri xlink:href="https://factfinder.census.gov/faces/tableservices/jsf/pages/productview.xhtml?src=CF]">https://factfinder.census.gov/faces/tableservices/jsf/pages/productview.xhtml?src=CF]</uri> [Accessed <comment>12 Aug 2019</comment>].</mixed-citation>
              </ref>
              <ref id="R72">
                <label>72</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Lazarin</surname><given-names>GA</given-names></string-name>, <string-name><surname>Haque</surname><given-names>IS</given-names></string-name>, <string-name><surname>Nazareth</surname><given-names>S</given-names></string-name>, <etal>et al</etal></person-group>. <article-title>An empirical estimate of carrier frequencies for 400+ causal Mendelian variants: Results from an ethnically diverse clinical sample of 23,453 individuals</article-title>. <source>Genet Med</source><year>2013</year>;<volume>15</volume>:<fpage>178</fpage>–<lpage>86</lpage>. <pub-id pub-id-type="doi">10.1038/gim.2012.114</pub-id>
<pub-id pub-id-type="pmid">22975760</pub-id></mixed-citation>
              </ref>
              <ref id="R73">
                <label>73</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Perlis</surname><given-names>N</given-names></string-name>, <string-name><surname>Connelly</surname><given-names>M</given-names></string-name>, <string-name><surname>D’A Honey</surname><given-names>JR</given-names></string-name>, <etal>et al</etal></person-group>. <article-title>Evaluating potential live-renal donors: causes for rejection, deferral and planned procedure type, a single-centre experience</article-title>. <source>Can Urol Assoc J</source><year>2013</year>;<volume>7</volume>:<fpage>41</fpage>–<lpage>5</lpage>. <pub-id pub-id-type="doi">10.5489/cuaj.216</pub-id>
<pub-id pub-id-type="pmid">23671492</pub-id></mixed-citation>
              </ref>
              <ref id="R74">
                <label>74</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Mena-Gutierrez</surname><given-names>AM</given-names></string-name>, <string-name><surname>Reeves-Daniel</surname><given-names>AM</given-names></string-name>, <string-name><surname>Jay</surname><given-names>CL</given-names></string-name>, <etal>et al</etal></person-group>. <article-title>Practical considerations for APOL1 genotyping in the living kidney donor evaluation</article-title>. <source>Transplantation</source><year>2020</year>;<volume>104</volume>:<fpage>27</fpage>–<lpage>32</lpage>. <pub-id pub-id-type="doi">10.1097/TP.0000000000002933</pub-id>
<pub-id pub-id-type="pmid">31449181</pub-id></mixed-citation>
              </ref>
              <ref id="R75">
                <label>75</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Gudsoorkar</surname><given-names>P</given-names></string-name>, <string-name><surname>Anand</surname><given-names>M</given-names></string-name>, <string-name><surname>Abu Jawdeh</surname><given-names>BG</given-names></string-name></person-group>. <article-title>APOL1 genotyping in potential African American living kidney donors: Utility and cost-effectiveness</article-title>. <source>Am J Nephrol</source><year>2020</year>;<volume>51</volume>:<fpage>116</fpage>–<lpage>8</lpage>. <pub-id pub-id-type="doi">10.1159/000505719</pub-id>
<pub-id pub-id-type="pmid">31940609</pub-id></mixed-citation>
              </ref>
              <ref id="R76">
                <label>76</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Owens</surname><given-names>OL</given-names></string-name>, <string-name><surname>Felder</surname><given-names>T</given-names></string-name>, <string-name><surname>Tavakoli</surname><given-names>AS</given-names></string-name>, <etal>et al</etal></person-group>. <article-title>Evaluation of a computer-based decision aid for promoting informed prostate cancer screening decisions among African American men: iDecide</article-title>. <source>AJHP</source><year>2019</year>;<volume>33</volume>:<fpage>267</fpage>–<lpage>78</lpage>. <pub-id pub-id-type="doi">10.1177/0890117118786866</pub-id>
<pub-id pub-id-type="pmid">29996666</pub-id></mixed-citation>
              </ref>
              <ref id="R77">
                <label>77</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Edwards</surname><given-names>RA</given-names></string-name>, <string-name><surname>Bickmore</surname><given-names>T</given-names></string-name>, <string-name><surname>Jenkins</surname><given-names>L</given-names></string-name>, <etal>et al</etal></person-group>. <article-title>Use of an interactive computer agent to support breastfeeding</article-title>. <source>Matern Child Health J</source><year>2013</year>;<volume>17</volume>:<fpage>1961</fpage>–<lpage>8</lpage>. <pub-id pub-id-type="doi">10.1007/s10995-013-1222-0</pub-id>
<pub-id pub-id-type="pmid">23329167</pub-id></mixed-citation>
              </ref>
              <ref id="R78">
                <label>78</label>
                <mixed-citation publication-type="book"><person-group person-group-type="author"><string-name><surname>Doshi</surname><given-names>MD</given-names></string-name>, <string-name><surname>Gordon</surname><given-names>EJ</given-names></string-name>, <string-name><surname>Freedman</surname><given-names>B</given-names></string-name></person-group>. <source>Physician Survey On Using APOL1 Genetic Testing In Live Kidney Donor Selection. Paper Presentation [20-A-3700-ATC]</source>. <publisher-loc>Philadelphia, PA</publisher-loc>: <publisher-name>American Transplant Congress</publisher-name>, <year>1202</year>: <fpage>0</fpage>.</mixed-citation>
              </ref>
              <ref id="R79">
                <label>79</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Smith</surname><given-names>JD</given-names></string-name>, <string-name><surname>Li</surname><given-names>DH</given-names></string-name>, <string-name><surname>Hirschhorn</surname><given-names>LR</given-names></string-name>, <etal>et al</etal></person-group>. <article-title>Landscape of HIV implementation research funded by the National Institutes of health: A mapping review of project Abstracts</article-title>. <source>AIDS Behav</source><year>2020</year>;<volume>24</volume>:<fpage>1903</fpage>–<lpage>11</lpage>. <pub-id pub-id-type="doi">10.1007/s10461-019-02764-6</pub-id>
<pub-id pub-id-type="pmid">31845078</pub-id></mixed-citation>
              </ref>
              <ref id="R80">
                <label>80</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Proctor</surname><given-names>EK</given-names></string-name>, <string-name><surname>Landsverk</surname><given-names>J</given-names></string-name>, <string-name><surname>Aarons</surname><given-names>G</given-names></string-name>, <etal>et al</etal></person-group>. <article-title>Implementation research in mental health services: An emerging science with conceptual, methodological, and training challenges</article-title>. <source>Adm Policy Ment Health</source><year>2009</year>;<volume>36</volume>:<fpage>24</fpage>–<lpage>34</lpage>. <pub-id pub-id-type="doi">10.1007/s10488-008-0197-4</pub-id>
<pub-id pub-id-type="pmid">19104929</pub-id></mixed-citation>
              </ref>
              <ref id="R81">
                <label>81</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Proctor</surname><given-names>E</given-names></string-name>, <string-name><surname>Silmere</surname><given-names>H</given-names></string-name>, <string-name><surname>Raghavan</surname><given-names>R</given-names></string-name>, <etal>et al</etal></person-group>. <article-title>Outcomes for implementation research: Conceptual distinctions, measurement challenges, and research agenda</article-title>. <source>Adm Policy Ment Health</source><year>2011</year>;<volume>38</volume>:<fpage>65</fpage>–<lpage>76</lpage>. <pub-id pub-id-type="doi">10.1007/s10488-010-0319-7</pub-id>
<pub-id pub-id-type="pmid">20957426</pub-id></mixed-citation>
              </ref>
              <ref id="R82">
                <label>82</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Smith</surname><given-names>JD</given-names></string-name>, <string-name><surname>Li</surname><given-names>DH</given-names></string-name>, <string-name><surname>Rafferty</surname><given-names>MR</given-names></string-name></person-group>. <article-title>The implementation research logic model: A method for planning, executing, reporting, and synthesizing implementation projects</article-title>. <source>Implement Sci</source><year>2020</year>;<volume>15</volume>. <pub-id pub-id-type="doi">10.1186/s13012-020-01041-8</pub-id></mixed-citation>
              </ref>
              <ref id="R83">
                <label>83</label>
                <mixed-citation publication-type="webpage"><person-group person-group-type="author"><collab>U.S. Census Bureau</collab></person-group>. <article-title>Population, ancestry, about, faqs</article-title>. <year>2017</year>. <comment>Available</comment>: <uri xlink:href="https://www.census.gov/topics/population/ancestry/about/faq.html#par_textimage_1]">https://www.census.gov/topics/population/ancestry/about/faq.html#par_textimage_1]</uri> [Accessed <comment>28 May 2017</comment>].</mixed-citation>
              </ref>
              <ref id="R84">
                <label>84</label>
                <mixed-citation publication-type="webpage"><person-group person-group-type="author"><collab>Statistics Canada</collab></person-group>. <article-title>National household survey 2011-N1</article-title>. <year>2015</year>. <comment>Available</comment>: <uri xlink:href="https://www12.statcan.gc.ca/nhs-enm/2011/ref/guides/99-010-x/99-010-x2011006-eng.cfm#a3">https://www12.statcan.gc.ca/nhs-enm/2011/ref/guides/99-010-x/99-010-x2011006-eng.cfm#a3</uri> [Accessed <comment>28 May 2020</comment>].</mixed-citation>
              </ref>
              <ref id="R85">
                <label>85</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Massie</surname><given-names>AB</given-names></string-name>, <string-name><surname>Muzaale</surname><given-names>AD</given-names></string-name>, <string-name><surname>Luo</surname><given-names>X</given-names></string-name>, <etal>et al</etal></person-group>. <article-title>Quantifying postdonation risk of ESRD in living kidney donors</article-title>. <source>JASN</source><year>2017</year>;<volume>28</volume>:<fpage>2749</fpage>–<lpage>55</lpage>. <pub-id pub-id-type="doi">10.1681/ASN.2016101084</pub-id>
<pub-id pub-id-type="pmid">28450534</pub-id></mixed-citation>
              </ref>
              <ref id="R86">
                <label>86</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Damschroder</surname><given-names>LJ</given-names></string-name>, <string-name><surname>Aron</surname><given-names>DC</given-names></string-name>, <string-name><surname>Keith</surname><given-names>RE</given-names></string-name>, <etal>et al</etal></person-group>. <article-title>Fostering implementation of health services research findings into practice: A consolidated framework for advancing implementation science</article-title>. <source>Implement Sci</source><year>2009</year>;<volume>4</volume>:<fpage>50</fpage>. <pub-id pub-id-type="doi">10.1186/1748-5908-4-50</pub-id><pub-id pub-id-type="pmid">19664226</pub-id></mixed-citation>
              </ref>
              <ref id="R87">
                <label>87</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Gaglio</surname><given-names>B</given-names></string-name>, <string-name><surname>Shoup</surname><given-names>JA</given-names></string-name>, <string-name><surname>Glasgow</surname><given-names>RE</given-names></string-name></person-group>. <article-title>The RE-AIM framework: A systematic review of use over time</article-title>. <source>Am J Public Health</source><year>2013</year>;<volume>103</volume>:<fpage>e38</fpage>–<lpage>46</lpage>. <pub-id pub-id-type="doi">10.2105/AJPH.2013.301299</pub-id>
</mixed-citation>
              </ref>
              <ref id="R88">
                <label>88</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Glasgow</surname><given-names>RE</given-names></string-name>, <string-name><surname>Harden</surname><given-names>SM</given-names></string-name>, <string-name><surname>Gaglio</surname><given-names>B</given-names></string-name>, <etal>et al</etal></person-group>. <article-title>RE-AIM planning and evaluation framework: Adapting to new science and practice with a 20-year review</article-title>. <source>Front Public Health</source><year>2019</year>;<volume>7</volume>:<fpage>64</fpage>. <pub-id pub-id-type="doi">10.3389/fpubh.2019.00064</pub-id><pub-id pub-id-type="pmid">30984733</pub-id></mixed-citation>
              </ref>
              <ref id="R89">
                <label>89</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Glasgow</surname><given-names>RE</given-names></string-name>, <string-name><surname>Klesges</surname><given-names>LM</given-names></string-name>, <string-name><surname>Dzewaltowski</surname><given-names>DA</given-names></string-name>, <etal>et al</etal></person-group>. <article-title>Evaluating the impact of health promotion programs: Using the RE-AIM framework to form summary measures for decision making involving complex issues</article-title>. <source>Health Educ Res</source><year>2006</year>;<volume>21</volume>:<fpage>688</fpage>–<lpage>94</lpage>. <pub-id pub-id-type="doi">10.1093/her/cyl081</pub-id>
<pub-id pub-id-type="pmid">16945984</pub-id></mixed-citation>
              </ref>
              <ref id="R90">
                <label>90</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Glasgow</surname><given-names>RE</given-names></string-name>, <string-name><surname>Vogt</surname><given-names>TM</given-names></string-name>, <string-name><surname>Boles</surname><given-names>SM</given-names></string-name></person-group>. <article-title>Evaluating the public health impact of health promotion interventions: The RE-AIM framework</article-title>. <source>Am J Public Health</source><year>1999</year>;<volume>89</volume>:<fpage>1322</fpage>–<lpage>7</lpage>. <pub-id pub-id-type="doi">10.2105/AJPH.89.9.1322</pub-id>
<pub-id pub-id-type="pmid">10474547</pub-id></mixed-citation>
              </ref>
              <ref id="R91">
                <label>91</label>
                <mixed-citation publication-type="book"><person-group person-group-type="author"><string-name><surname>Green</surname><given-names>J</given-names></string-name>, <string-name><surname>Thorogood</surname><given-names>N</given-names></string-name></person-group>. <source>Qualitative Methods for Health Research,</source><edition>3rd Edition</edition>. <publisher-loc>Los Angeles, CA</publisher-loc>: <publisher-name>Sage Publications</publisher-name>, <year>2014</year>.</mixed-citation>
              </ref>
              <ref id="R92">
                <label>92</label>
                <mixed-citation publication-type="book"><person-group person-group-type="author"><string-name><surname>Spradley</surname><given-names>J</given-names></string-name></person-group>. <source>The Ethnographic Interview</source>. <publisher-loc>New York</publisher-loc>: <publisher-name>Harcourt Brace Jovanovich</publisher-name>, <year>1979</year>.</mixed-citation>
              </ref>
              <ref id="R93">
                <label>93</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Weiner</surname><given-names>BJ</given-names></string-name>, <string-name><surname>Lewis</surname><given-names>CC</given-names></string-name>, <string-name><surname>Stanick</surname><given-names>C</given-names></string-name>, <etal>et al</etal></person-group>. <article-title>Psychometric assessment of three newly developed implementation outcome measures</article-title>. <source>Implement Sci</source><year>2017</year>;<volume>12</volume>. <pub-id pub-id-type="doi">10.1186/s13012-017-0635-3</pub-id></mixed-citation>
              </ref>
              <ref id="R94">
                <label>94</label>
                <mixed-citation publication-type="book"><person-group person-group-type="author"><string-name><surname>Singleton</surname><given-names>R</given-names></string-name>, <string-name><surname>Straits</surname><given-names>B</given-names></string-name></person-group>. <source>Approaches to Social Research,</source><edition>Fourth Edition</edition>. <publisher-loc>New York</publisher-loc>: <publisher-name>Oxford University Press</publisher-name>, <year>2005</year>.</mixed-citation>
              </ref>
              <ref id="R95">
                <label>95</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Stiles</surname><given-names>PG</given-names></string-name>, <string-name><surname>Boothroyd</surname><given-names>RA</given-names></string-name>, <string-name><surname>Snyder</surname><given-names>K</given-names></string-name>, <etal>et al</etal></person-group>. <article-title>Service penetration by persons with severe mental illness: How should it be measured?</article-title><source>J Behav Health Serv Res</source><year>2002</year>;<volume>29</volume>:<fpage>198</fpage>–<lpage>207</lpage>. <pub-id pub-id-type="doi">10.1007/BF02287706</pub-id>
<pub-id pub-id-type="pmid">12032977</pub-id></mixed-citation>
              </ref>
              <ref id="R96">
                <label>96</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Shelton</surname><given-names>RC</given-names></string-name>, <string-name><surname>Chambers</surname><given-names>DA</given-names></string-name>, <string-name><surname>Glasgow</surname><given-names>RE</given-names></string-name></person-group>. <article-title>An extension of RE-AIM to enhance sustainability: Addressing dynamic context and promoting health equity over time</article-title>. <source>Front Public Health</source><year>2020</year>;<volume>8</volume>:<elocation-id>134</elocation-id>. <pub-id pub-id-type="doi">10.3389/fpubh.2020.00134</pub-id><pub-id pub-id-type="pmid">32478025</pub-id></mixed-citation>
              </ref>
              <ref id="R97">
                <label>97</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Hooker</surname><given-names>GW</given-names></string-name>, <string-name><surname>Babu</surname><given-names>D</given-names></string-name>, <string-name><surname>Myers</surname><given-names>MF</given-names></string-name>, <etal>et al</etal></person-group>. <article-title>Standards for the reporting of genetic counseling interventions in research and other studies (GCIRS): An NSGC Task Force report</article-title>. <source>J Genet Couns</source><year>2017</year>;<volume>26</volume>:<fpage>355</fpage>–<lpage>60</lpage>. <pub-id pub-id-type="doi">10.1007/s10897-017-0076-9</pub-id>
<pub-id pub-id-type="pmid">28236280</pub-id></mixed-citation>
              </ref>
              <ref id="R98">
                <label>98</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Rohrbach</surname><given-names>LA</given-names></string-name>, <string-name><surname>Gunning</surname><given-names>M</given-names></string-name>, <string-name><surname>Sun</surname><given-names>P</given-names></string-name>, <etal>et al</etal></person-group>. <article-title>The project towards no drug abuse (TND) dissemination trial: Implementation fidelity and immediate outcomes</article-title>. <source>Prevention Science</source><year>2010</year>;<volume>11</volume>:<fpage>77</fpage>–<lpage>88</lpage>. <pub-id pub-id-type="doi">10.1007/s11121-009-0151-z</pub-id>
<pub-id pub-id-type="pmid">19757052</pub-id></mixed-citation>
              </ref>
              <ref id="R99">
                <label>99</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Feely</surname><given-names>M</given-names></string-name>, <string-name><surname>Seay</surname><given-names>KD</given-names></string-name>, <string-name><surname>Lanier</surname><given-names>P</given-names></string-name>, <etal>et al</etal></person-group>. <article-title>Measuring fidelity in research studies: A field guide to developing a comprehensive fidelity measurement system</article-title>. <source>Child Adolesc Soc Work J</source><year>2018</year>;<volume>35</volume>:<fpage>139</fpage>–<lpage>52</lpage>. <pub-id pub-id-type="doi">10.1007/s10560-017-0512-6</pub-id>
</mixed-citation>
              </ref>
              <ref id="R100">
                <label>100</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Wiltsey Stirman</surname><given-names>S</given-names></string-name>, <string-name><surname>Baumann</surname><given-names>AA</given-names></string-name>, <string-name><surname>Miller</surname><given-names>CJ</given-names></string-name></person-group>. <article-title>The frame: An expanded framework for reporting adaptations and modifications to evidence-based interventions</article-title>. <source>Implement Sci</source><year>2019</year>;<volume>14</volume>:<fpage>58</fpage>. <pub-id pub-id-type="doi">10.1186/s13012-019-0898-y</pub-id><pub-id pub-id-type="pmid">31171014</pub-id></mixed-citation>
              </ref>
              <ref id="R101">
                <label>101</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Gordon</surname><given-names>EJ</given-names></string-name>, <string-name><surname>Uriarte</surname><given-names>JJ</given-names></string-name>, <string-name><surname>Anderson</surname><given-names>N</given-names></string-name>, <etal>et al</etal></person-group>. <article-title>Sustainment of a complex culturally competent care intervention for Hispanic living donor kidney transplantation: A longitudinal analysis of adaptations</article-title>. <source>J Clin Transl Sci</source><year>2022</year>;<volume>6</volume>:<elocation-id>e38</elocation-id>. <pub-id pub-id-type="doi">10.1017/cts.2022.378</pub-id><pub-id pub-id-type="pmid">35574156</pub-id></mixed-citation>
              </ref>
              <ref id="R102">
                <label>102</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Malone</surname><given-names>S</given-names></string-name>, <string-name><surname>Prewitt</surname><given-names>K</given-names></string-name>, <string-name><surname>Hackett</surname><given-names>R</given-names></string-name>, <etal>et al</etal></person-group>. <article-title>The clinical sustainability assessment tool: Measuring organizational capacity to promote sustainability in healthcare</article-title>. <source>Implement Sci Commun</source><year>2021</year>;<volume>2</volume>:<fpage>77</fpage>. <pub-id pub-id-type="doi">10.1186/s43058-021-00181-2</pub-id><pub-id pub-id-type="pmid">34274004</pub-id></mixed-citation>
              </ref>
              <ref id="R103">
                <label>103</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Peter</surname><given-names>B</given-names></string-name>, <string-name><surname>Dougherty</surname><given-names>MJ</given-names></string-name>, <string-name><surname>Reed</surname><given-names>EK</given-names></string-name>, <etal>et al</etal></person-group>. <article-title>Perceived gaps in genetics training among audiologists and speech-language pathologists: Lessons from a national survey</article-title>. <source>Am J Speech Lang Pathol</source><year>2019</year>;<volume>28</volume>:<fpage>408</fpage>–<lpage>23</lpage>. <pub-id pub-id-type="doi">10.1044/2018_AJSLP-18-0069</pub-id>
<pub-id pub-id-type="pmid">31091132</pub-id></mixed-citation>
              </ref>
              <ref id="R104">
                <label>104</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Reed</surname><given-names>EK</given-names></string-name>, <string-name><surname>Johansen Taber</surname><given-names>KA</given-names></string-name>, <string-name><surname>Ingram Nissen</surname><given-names>T</given-names></string-name>, <etal>et al</etal></person-group>. <article-title>What works in genomics education: Outcomes of an evidenced-based instructional model for community-based physicians</article-title>. <source>Genet Med</source><year>2016</year>;<volume>18</volume>:<fpage>737</fpage>–<lpage>45</lpage>. <pub-id pub-id-type="doi">10.1038/gim.2015.144</pub-id>
<pub-id pub-id-type="pmid">26583682</pub-id></mixed-citation>
              </ref>
              <ref id="R105">
                <label>105</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Bonham</surname><given-names>VL</given-names></string-name>, <string-name><surname>Sellers</surname><given-names>SL</given-names></string-name>, <string-name><surname>Woolford</surname><given-names>S</given-names></string-name></person-group>. <article-title>Physicians' knowledge, beliefs, and use of race and human genetic variation: New measures and insights</article-title>. <source>BMC Health Serv Res</source><year>2014</year>;<volume>14</volume>:<elocation-id>456</elocation-id>. <pub-id pub-id-type="doi">10.1186/1472-6963-14-456</pub-id><pub-id pub-id-type="pmid">25277068</pub-id></mixed-citation>
              </ref>
              <ref id="R106">
                <label>106</label>
                <mixed-citation publication-type="book"><person-group person-group-type="author"><string-name><surname>Bernard</surname><given-names>H</given-names></string-name>, <string-name><surname>Ryan</surname><given-names>G</given-names></string-name></person-group>. <part-title>Text analysis: Qualitative and quantitative methods</part-title>. In: <person-group person-group-type="editor"><string-name><surname>Bernard</surname><given-names>H</given-names></string-name></person-group>, ed. <source>Handbook of Methods in Cultural Anthropology</source>. <publisher-loc>Walnut Creek, CA</publisher-loc>: <publisher-name>Altamira Press</publisher-name>, <year>1998</year>: <fpage>595</fpage>–<lpage>646</lpage>.</mixed-citation>
              </ref>
              <ref id="R107">
                <label>107</label>
                <mixed-citation publication-type="book"><person-group person-group-type="author"><string-name><surname>Guest</surname><given-names>G</given-names></string-name>, <string-name><surname>MacQueen</surname><given-names>K</given-names></string-name>, <string-name><surname>Namey</surname><given-names>E</given-names></string-name></person-group>. <part-title>Applied thematic analysis</part-title>. In: <source>Applied Thematic Analysis</source>. <publisher-loc>Thousand Oaks, CA</publisher-loc>: <publisher-name>Sage Publishers</publisher-name>, <year>2012</year>. <pub-id pub-id-type="doi">10.4135/9781483384436</pub-id></mixed-citation>
              </ref>
              <ref id="R108">
                <label>108</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Lincoln</surname><given-names>YS</given-names></string-name>, <string-name><surname>Guba</surname><given-names>EG</given-names></string-name>, <string-name><surname>Pilotta</surname><given-names>JJ</given-names></string-name></person-group>. <article-title>Naturalistic inquiry</article-title>. <source>Int J Intercult Relat</source><year>1985</year>;<volume>9</volume>:<fpage>438</fpage>–<lpage>9</lpage>. <pub-id pub-id-type="doi">10.1016/0147-1767(85)90062-8</pub-id>
</mixed-citation>
              </ref>
              <ref id="R109">
                <label>109</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Bradley</surname><given-names>EH</given-names></string-name>, <string-name><surname>Curry</surname><given-names>LA</given-names></string-name>, <string-name><surname>Devers</surname><given-names>KJ</given-names></string-name></person-group>. <article-title>Qualitative data analysis for health services research: Developing taxonomy, themes, and theory</article-title>. <source>Health Services Research</source><year>2007</year>;<volume>42</volume>:<fpage>1758</fpage>–<lpage>72</lpage>. <pub-id pub-id-type="doi">10.1111/j.1475-6773.2006.00684.x</pub-id>
<pub-id pub-id-type="pmid">17286625</pub-id></mixed-citation>
              </ref>
              <ref id="R110">
                <label>110</label>
                <mixed-citation publication-type="book"><person-group person-group-type="author"><string-name><surname>Miles</surname><given-names>M</given-names></string-name>, <string-name><surname>Huberman</surname><given-names>A</given-names></string-name></person-group>. <source>Qualitative Data Analysis: An Expanded Sourcebook,</source><edition>Second Edition</edition>. <publisher-loc>Thousand Oaks, CA</publisher-loc>: <publisher-name>Sage Publications</publisher-name>, <year>1994</year>.</mixed-citation>
              </ref>
              <ref id="R111">
                <label>111</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Giacomini</surname><given-names>MK</given-names></string-name>, <string-name><surname>Cook</surname><given-names>DJ</given-names></string-name>, <string-name><surname>Group</surname><given-names>E-B</given-names></string-name>, <etal>et al</etal></person-group>. <article-title>Users' guides to the medical literature: XXIII. Qualitative research in health care A. Are the results of the study valid</article-title>. <source>JAMA</source><year>2000</year>;<volume>284</volume>:<fpage>357</fpage>–<lpage>62</lpage>. <pub-id pub-id-type="doi">10.1001/jama.284.3.357</pub-id>
<pub-id pub-id-type="pmid">10891968</pub-id></mixed-citation>
              </ref>
              <ref id="R112">
                <label>112</label>
                <mixed-citation publication-type="book"><person-group person-group-type="author"><string-name><surname>Guest</surname><given-names>G</given-names></string-name>, <string-name><surname>MacQueen</surname><given-names>K</given-names></string-name>, <string-name><surname>Namey</surname><given-names>E</given-names></string-name></person-group>. <source>Applied Thematic Analysis</source>. <publisher-loc>Thousand Oaks, CA</publisher-loc>: <publisher-name>Sage Publications, Inc</publisher-name>, <year>2012</year>: <fpage>79</fpage>–<lpage>106</lpage>.</mixed-citation>
              </ref>
              <ref id="R113">
                <label>113</label>
                <mixed-citation publication-type="book"><person-group person-group-type="author"><string-name><surname>Guba</surname><given-names>E</given-names></string-name>, <string-name><surname>Lincoln</surname><given-names>Y</given-names></string-name></person-group>. <source>Fourth Generation Evaluation</source>. <publisher-loc>Newbury Park, CA</publisher-loc>: <publisher-name>Sage Publications</publisher-name>, <year>1989</year>.</mixed-citation>
              </ref>
              <ref id="R114">
                <label>114</label>
                <mixed-citation publication-type="book"><person-group person-group-type="author"><collab>Centers for Disease Control and Prevention (CDC)</collab></person-group>. <source>2009 Behavioral Risk Factor Surveillance System Survey Questionnaire</source>. <publisher-loc>Atlanta, Georgia</publisher-loc>: <publisher-name>U.S. Department of Health and Human Services, Centers for Disease Control and Prevention</publisher-name>, <year>2009</year>. <comment>Available</comment>: <uri xlink:href="http://www.cdc.gov/brfss/">http://www.cdc.gov/brfss/</uri></mixed-citation>
              </ref>
              <ref id="R115">
                <label>115</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Baker</surname><given-names>D</given-names></string-name>, <string-name><surname>Cameron</surname><given-names>K</given-names></string-name>, <string-name><surname>Feinglass</surname><given-names>J</given-names></string-name>, <etal>et al</etal></person-group>. <article-title>Development and testing of a system to rapidly and accurately collect patients’ race and ethnicity</article-title>. <source>Am J Public Health</source><year>2006</year>;<volume>96</volume>:<fpage>532</fpage>–<lpage>7</lpage>.<pub-id pub-id-type="pmid">16449590</pub-id></mixed-citation>
              </ref>
              <ref id="R116">
                <label>116</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Hasnain-Wynia</surname><given-names>R</given-names></string-name>, <string-name><surname>Baker</surname><given-names>DW</given-names></string-name></person-group>. <article-title>Obtaining data on patient race, ethnicity, and primary language in health care organizations: Current challenges and proposed solutions</article-title>. <source>Health Serv Res</source><year>2006</year>;<volume>41</volume>(<issue>4 Pt 1</issue>):<fpage>1501</fpage>–<lpage>18</lpage>.:<elocation-id>060720074824036</elocation-id>. <pub-id pub-id-type="doi">10.1111/j.1475-6773.2006.00552.x</pub-id>
<comment>Available</comment>: <uri xlink:href="http://www.blackwell-synergy.com/toc/hesr/0/0">http://www.blackwell-synergy.com/toc/hesr/0/0</uri>
<pub-id pub-id-type="pmid">16899021</pub-id></mixed-citation>
              </ref>
              <ref id="R117">
                <label>117</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Singh</surname><given-names>R</given-names></string-name>, <string-name><surname>Coyne</surname><given-names>LS</given-names></string-name>, <string-name><surname>Wallace</surname><given-names>LS</given-names></string-name></person-group>. <article-title>Brief screening items to identify Spanish-speaking adults with limited health literacy and numeracy skills</article-title>. <source>BMC Health Serv Res</source><year>2015</year>;<volume>15</volume>:<elocation-id>374</elocation-id>. <pub-id pub-id-type="doi">10.1186/s12913-015-1046-2</pub-id><pub-id pub-id-type="pmid">26370120</pub-id></mixed-citation>
              </ref>
              <ref id="R118">
                <label>118</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Sieverdes</surname><given-names>JC</given-names></string-name>, <string-name><surname>Nemeth</surname><given-names>LS</given-names></string-name>, <string-name><surname>Magwood</surname><given-names>GS</given-names></string-name>, <etal>et al</etal></person-group>. <article-title>Patient-Centered mHealth living donor transplant education program for African Americans: Development and analysis</article-title>. <source>JMIR Res Protoc</source><year>2015</year>;<volume>4</volume>:<elocation-id>e84</elocation-id>. <pub-id pub-id-type="doi">10.2196/resprot.3715</pub-id><pub-id pub-id-type="pmid">26265532</pub-id></mixed-citation>
              </ref>
              <ref id="R119">
                <label>119</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Ostergren</surname><given-names>JE</given-names></string-name>, <string-name><surname>Gornick</surname><given-names>MC</given-names></string-name>, <string-name><surname>Carere</surname><given-names>DA</given-names></string-name>, <etal>et al</etal></person-group>. <article-title>How well do customers of direct-to-consumer personal genomic testing services Comprehend genetic test results? Findings from the impact of personal genomics study</article-title>. <source>Public Health Genom</source><year>2015</year>;<volume>18</volume>:<fpage>216</fpage>–<lpage>24</lpage>. <pub-id pub-id-type="doi">10.1159/000431250</pub-id>
</mixed-citation>
              </ref>
              <ref id="R120">
                <label>120</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Carere</surname><given-names>DA</given-names></string-name>, <string-name><surname>Kraft</surname><given-names>P</given-names></string-name>, <string-name><surname>Kaphingst</surname><given-names>KA</given-names></string-name>, <etal>et al</etal></person-group>. <article-title>Consumers report lower confidence in their genetics knowledge following direct-to-consumer personal genomic testing</article-title>. <source>Genet Med</source><year>2016</year>;<volume>18</volume>:<fpage>65</fpage>–<lpage>72</lpage>. <pub-id pub-id-type="doi">10.1038/gim.2015.34</pub-id>
<pub-id pub-id-type="pmid">25812042</pub-id></mixed-citation>
              </ref>
              <ref id="R121">
                <label>121</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Kaphingst</surname><given-names>KA</given-names></string-name>, <string-name><surname>McBride</surname><given-names>CM</given-names></string-name>, <string-name><surname>Wade</surname><given-names>C</given-names></string-name>, <etal>et al</etal></person-group>. <article-title>Patients' understanding of and responses to Multiplex genetic susceptibility test results</article-title>. <source>Genet Med</source><year>2012</year>;<volume>14</volume>:<fpage>681</fpage>–<lpage>7</lpage>. <pub-id pub-id-type="doi">10.1038/gim.2012.22</pub-id>
<pub-id pub-id-type="pmid">22481132</pub-id></mixed-citation>
              </ref>
              <ref id="R122">
                <label>122</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>O’Connor</surname><given-names>AM</given-names></string-name></person-group>. <article-title>Validation of a decisional conflict scale</article-title>. <source>Med Decis Making</source><year>1995</year>;<volume>15</volume>:<fpage>25</fpage>–<lpage>30</lpage>. <pub-id pub-id-type="doi">10.1177/0272989X9501500105</pub-id>
<pub-id pub-id-type="pmid">7898294</pub-id></mixed-citation>
              </ref>
              <ref id="R123">
                <label>123</label>
                <mixed-citation publication-type="book"><person-group person-group-type="author"><collab>O'Connor AM</collab></person-group>. <source>User Manual - Decisional Conflict Scale (16 item statement format) document on the Internet</source>. <publisher-loc>Ottawa</publisher-loc>: <publisher-name>Ottawa Hospital Research Institute</publisher-name>, <year>2010</year><comment>Available</comment>. <uri xlink:href="https://decisionaid.ohri.ca/docs/develop/User_Manuals/UM_Decisional_Conflict.pdf">https://decisionaid.ohri.ca/docs/develop/User_Manuals/UM_Decisional_Conflict.pdf</uri></mixed-citation>
              </ref>
              <ref id="R124">
                <label>124</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Garvelink</surname><given-names>MM</given-names></string-name>, <string-name><surname>Boland</surname><given-names>L</given-names></string-name>, <string-name><surname>Klein</surname><given-names>K</given-names></string-name>, <etal>et al</etal></person-group>. <article-title>Decisional conflict scale use over 20 years: The anniversary review</article-title>. <source>Med Decis Making</source><year>2019</year>;<volume>39</volume>:<fpage>301</fpage>–<lpage>14</lpage>. <pub-id pub-id-type="doi">10.1177/0272989X19851345</pub-id>
<pub-id pub-id-type="pmid">31142194</pub-id></mixed-citation>
              </ref>
              <ref id="R125">
                <label>125</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Bennett</surname><given-names>C</given-names></string-name>, <string-name><surname>Graham</surname><given-names>ID</given-names></string-name>, <string-name><surname>Kristjansson</surname><given-names>E</given-names></string-name>, <etal>et al</etal></person-group>. <article-title>Validation of a preparation for decision making scale</article-title>. <source>Patient Educ Couns</source><year>2010</year>;<volume>78</volume>:<fpage>130</fpage>–<lpage>3</lpage>. <pub-id pub-id-type="doi">10.1016/j.pec.2009.05.012</pub-id>
<pub-id pub-id-type="pmid">19560303</pub-id></mixed-citation>
              </ref>
              <ref id="R126">
                <label>126</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Guidry</surname><given-names>JJ</given-names></string-name>, <string-name><surname>Walker</surname><given-names>VD</given-names></string-name></person-group>. <article-title>Assessing cultural sensitivity in printed cancer materials</article-title>. <source>Cancer Practice</source><year>1999</year>;<volume>7</volume>:<fpage>291</fpage>–<lpage>6</lpage>. <pub-id pub-id-type="doi">10.1046/j.1523-5394.1999.76005.x</pub-id>
<pub-id pub-id-type="pmid">10732526</pub-id></mixed-citation>
              </ref>
              <ref id="R127">
                <label>127</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Friedman</surname><given-names>DB</given-names></string-name>, <string-name><surname>Kao</surname><given-names>EK</given-names></string-name></person-group>. <article-title>A comprehensive assessment of the difficulty level and cultural sensitivity of online cancer prevention resources for older minority men</article-title>. <source>Prev Chronic Dis</source><year>2008</year>;<volume>5</volume>:<elocation-id>A07</elocation-id>.<pub-id pub-id-type="pmid">18081996</pub-id></mixed-citation>
              </ref>
              <ref id="R128">
                <label>128</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Kriston</surname><given-names>L</given-names></string-name>, <string-name><surname>Scholl</surname><given-names>I</given-names></string-name>, <string-name><surname>Hölzel</surname><given-names>L</given-names></string-name>, <etal>et al</etal></person-group>. <article-title>The 9-item shared decision making questionnaire (SDM-Q-9). development and Psychometric properties in a primary care sample</article-title>. <source>Patient Educ Couns</source><year>2010</year>;<volume>80</volume>:<fpage>94</fpage>–<lpage>9</lpage>. <pub-id pub-id-type="doi">10.1016/j.pec.2009.09.034</pub-id>
<pub-id pub-id-type="pmid">19879711</pub-id></mixed-citation>
              </ref>
              <ref id="R129">
                <label>129</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Fink</surname><given-names>AS</given-names></string-name>, <string-name><surname>Prochazka</surname><given-names>AV</given-names></string-name>, <string-name><surname>Henderson</surname><given-names>WG</given-names></string-name>, <etal>et al</etal></person-group>. <article-title>Enhancement of surgical informed consent by addition of repeat back: A multicenter, randomized controlled clinical trial</article-title>. <source>Ann Surg</source><year>2010</year>;<volume>252</volume>:<fpage>27</fpage>–<lpage>36</lpage>. <pub-id pub-id-type="doi">10.1097/SLA.0b013e3181e3ec61</pub-id>
<pub-id pub-id-type="pmid">20562609</pub-id></mixed-citation>
              </ref>
              <ref id="R130">
                <label>130</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Fink</surname><given-names>AS</given-names></string-name>, <string-name><surname>Prochazka</surname><given-names>AV</given-names></string-name>, <string-name><surname>Henderson</surname><given-names>WG</given-names></string-name>, <etal>et al</etal></person-group>. <article-title>Predictors of comprehension during surgical informed consent</article-title>. <source>J Am Coll Surg</source><year>2010</year>;<volume>210</volume>:<fpage>919</fpage>–<lpage>26</lpage>. <pub-id pub-id-type="doi">10.1016/j.jamcollsurg.2010.02.049</pub-id>
<pub-id pub-id-type="pmid">20510800</pub-id></mixed-citation>
              </ref>
              <ref id="R131">
                <label>131</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Brehaut</surname><given-names>JC</given-names></string-name>, <string-name><surname>O’Connor</surname><given-names>AM</given-names></string-name>, <string-name><surname>Wood</surname><given-names>TJ</given-names></string-name>, <etal>et al</etal></person-group>. <article-title>Validation of a decision regret scale</article-title>. <source>Med Decis Making</source><year>2003</year>;<volume>23</volume>:<fpage>281</fpage>–<lpage>92</lpage>. <pub-id pub-id-type="doi">10.1177/0272989X03256005</pub-id>
<pub-id pub-id-type="pmid">12926578</pub-id></mixed-citation>
              </ref>
              <ref id="R132">
                <label>132</label>
                <mixed-citation publication-type="confproc"><person-group person-group-type="author"><string-name><surname>Luke</surname><given-names>DA</given-names></string-name>, <string-name><surname>Malone</surname><given-names>S</given-names></string-name>, <string-name><surname>Prewitt</surname><given-names>K</given-names></string-name>, <etal>et al</etal></person-group>. <article-title>The clinical sustainability assessment tool (CSAT): Assessing sustainability in clinical medicine settings</article-title>. <conf-name>Conference on the Science of Dissemination and Implementation in Health</conf-name>; <publisher-loc>Washington, DC</publisher-loc>, <year>2018</year></mixed-citation>
              </ref>
            </ref-list>
          </back>
        </article>
      </metadata>
    </record>
  </GetRecord>
</OAI-PMH>
